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Zusammenfassung
Seit Linearbeschleuniger fu¨r medizinische Zwecke verwendet werden, ist der Ausgleich-
filter ein wichtiger Bestandteil des Beschleunigers. Er kompensiert den lateral nicht
uniformen Teil, der durch Bremsstrahlung erzeugten Photonenfluenz und vereinfacht
dadurch die Dosisberechnung vor allem, wenn mehrere Felder kombiniert werden. Mit
der Einfu¨hrung von modernen Planungstechniken, wie Intensita¨ts-modulierter Strahlen-
therapie (IMRT) und Volumen-modulierter Bogenbestrahlung (VMAT), die die Fluen-
zverteilung dynamisch anpassen, ist es nicht mehr unbedingt no¨tig, dass das initiale
Fluenzprofil homogen ist. Basierend auf dieser Annahme wurden Ausgleichsfilter-freie
(Flattening Filter Free: FFF) Strahlqualita¨ten interessant fu¨r die klinische Anwendung
vor allem bei Therapieansa¨tzen mit hoher Einzeldosis. Im Rahmen dieser Arbeit wurden
verschiedene Aspekte untersucht, die den klinischen Nutzen von FFF Strahlqualita¨ten
na¨ber beleuchten.
Zuna¨chst wurden die dosimetrischen Eigenschaften eines neuen Beschleunigertyps (True-
Beam, Varian Medical Systems), an dem sowohl FFF als auch konventionelle Strahl-
qualita¨ten mit Ausgleichsfilter (FF) verfu¨gbar sind, untersucht. Fu¨r FF wie auch fu¨r
FFF Strahlen mit nomineller Energie von 6 und 10 MV (X6, X6FFF, X10, X10FFF)
wurden Tiefendosiskurven, Querprofile, Oberfla¨chendosen, Halbschatten, Dosen ausser-
halb des Feldes sowie Streufaktoren untersucht und verglichen. Es hat sich gezeigt, dass
FFF Strahlen eine niedrigere mittlere Energie haben (Gewebe-Phantom Verha¨ltnisse bei
den Tiefen 20 cm und 10 cm (TPR 20/10): X6 0.667; X6FFF 0.631; X10 0.738; X10FFF:
0.692); das Dosismaximum na¨her an der Oberfla¨che liegt; und die Oberfla¨chendosis um
10% erho¨ht ist. FFF Profile haben einen schmaleren Halbschatten nahe der Oberfla¨che
der sich aber mit zunehmender Tiefe schneller verbreitert im Vergleich zu den FF
Strahlen. Fu¨r kleine Feldgro¨ssen und nahe der Oberfla¨che ist die Dosis ausserhalb
des Feldes fu¨r FFF Strahlen reduziert, der Vorteil verschwindet jedoch aufgrund der
ix
erho¨hten Phantomstreuung mit zunehmender Feldgro¨sse und zunehmender Tiefe. Die
maximale Dosisleistung im Zentrum erho¨ht sich um einen Faktor 2.26 fu¨r X6FFF und
einen Faktor 4.03 fu¨r X10FFF. Ausserdem ist die Feldgro¨ssenfaktor weniger von der
Feldgro¨sse im Vergleich zu den FF Strahlen.
Die Genauigkeit der Strahlmodellierung mit dem anisotropischen analytischen Algorith-
mus (AAA, Varian Medical Systems) wurde untersucht, indem das Strahlmodell mit
im Wasserphantom gemessenen Daten verglichen wurde. Obwohl die FFF Strahlen
mit einem einfacheren AAA Modell modelliert werden, ist die Genauigkeit vergleichbar
mit der der konventionellen Strahlen. Diese Ergebnisse stu¨tzen die Annahme, dass die
Entfernung des Ausgleichfilters die Modellierung vereinfacht (weniger A¨nderung des En-
ergiespektrums entlang des Feldnormalen, weniger gestreute Photonen, etc.). Mit Hilfe
der γ-Analyse wurde gezeigt, dass alle Punkte das Kriterium von 2 mm Entfernung bis
zur U¨bereinstimmung und 2 % Dosisdifferenz erfu¨llen.
Die γ-Analyse basiert auf einem modifizierten ein dimensionalen γ-Konzept. Der Algo-
rithmus funktioniert folgendermassen: Erst wird ein lokaler Fit der Referenz- und der
auszuwertenden Kurve gemacht. Fu¨r jeden Punkt auf der gefitteten auszuwertenden
Kurve werden die γ-Werte ermittelt, als ku¨rzester Abstand bis zur U¨bereinstimmung
zwischen den Punkten auf der auszuwertenden Kurve und dem Fit der Referenz-Kurve.
Diese Vorgehen vermeidet Abweichungen und Fehler des γ-Wertes aufgrund des diskreten
Messpunkte und des Rauschens im Datensatz. Initial wurde diese Analysesoftware
entwickelt, um zwei Datensa¨tze von Kommissionierungsdaten zu vergleichen. Damit
kann jedoch dank der Universalita¨t der Methodik jede Art von ein-dimensionalen Do-
sisverteilungen verglichen werden.
Als Vorbereitung fu¨r die Kommissionierungsarbeiten mussten die dosimetrischen Eigen-
schaften der Ionisationskammern in den FFF Strahlen mit hohen Dosisraten (bis 25 Gy
min−1), untersucht werden. In den konventionellen FFF Strahlen war die Ionensam-
meleffizienz fu¨r alle luft-gefu¨llten Ionisationskammern u¨ber 0.995. In den FFF Strahlen
war die Ionensammeleffizienz genu¨gend hoch, um eine akkurate Relativdosimetrie zu
garantieren, die Korrekturfaktoren fu¨r die Absolutdosimetrie waren unter 1% fu¨r beide
FFF Strahlqualita¨ten. Jedoch war die Ionensammeleffizienz in den FFF Strahlen nicht
ausreichend fu¨r eine Isooctan-gefu¨llte Ionisationskammer. Diese Kammer kann nicht fu¨r
Relativdosimetrie empfohlen werden.
Radiobiologische Effekte im Zusammenhang mit FFF Strahlen wurden in zwei men-
schlichen Glioblastoma Zelllinien untersucht. Dosen bis zwanzig Gray wurden mit ver-
schiedenen Dosisleistungen und Energien appliziert. Die Dosis wurde mit Hilfen von
Filmen wie auch mit Ionisationskammern verifiziert und die Koloniebildungsfa¨higkeit
wurde in Assays ausgewertet. Unsere Daten wurden gestu¨tzt von einer radiobiologis-
chen Modellierung der Daten. Es zeigte sich, dass das klonogene U¨berleben statistisch
signifikant reduziert wird, wenn die Gesamtdosis mit einer erho¨hten Dosis pro Puls aber
der gleichen Dosisleistung appliziert wird. Ausserdem wurde gezeigt, dass es keine Un-
terschiede zwischen dem U¨berleben gibt, wenn die Dosis mit X10FFF oder X10 bei der
gleichen Dosis pro Puls appliziert wird. Daraus folgt, dass weder das unterschiedliche
Spektrum noch die Pulsfrequenz einen Einfluss auf das U¨berleben hat.
Es wurden zwei Planungsstudien durchgefu¨hrt, die den Effekt von FFF Strahlen sowohl
auf die Planqualita¨t als auch auf die Behandlungseffizienz untersuchen. Die eine Studie
fokussierte auf nicht-kleinzellige Lungentumore die andere auf lokalisierte Prostatakarzi-
nome. Beide Studien haben gezeigt, dass mit konventionelle und FFF Strahlqualita¨ten
vergleichbare dosimetrische Ergebnisse erreicht werden ko¨nnen; nur kleine Unterschiede
wurden gefunden. Jedoch wurde die Behandlungseffizienz in beiden Studien deutlich
gesteigert, wenn FFF Strahlen zur Behandlung benutzt wurden.
Im Rahmen der Lungenstudie erreichte man konformale Dosisverteilungen (Konfor-
mita¨tsindex: CI<1.17) und scharfe Dosisgradienten ausserhalb des Planungszielvolu-
mens (PTV). Das Verha¨ltnis der Monitoreinheiten zwischen FFF und FF Strahlqualita¨ten
bewegte sich zwischen 0.95 bis 1.21 fu¨r X6FFF/X6FF und zwischen 0.93 bis 1.25 fu¨r
X10FFF/X6FF. Der Vergleich des kumulierten Dosis-Volumen-Histogramms fu¨r das
Zielvolumen und den Ko¨rper hat gezeigt, dass mit der X6FFF Strahlqualita¨t eine bessere
Konformita¨t erreicht werden kann und das Volumen, das mehr als 50 % der verschriebe-
nen Dosis bekommt, reduziert werden kann. Alle Parameter, die den Dosisgradienten
beschreiben, zeigten eine statistisch signifikante Verbesserung. CI50%, CI60%, CI80%,
und CI100% waren im Mittel reduziert um 4.6 % (p<0.001), 4.6 % (p=0.002), 3.1
% (p=0.002), und 1.2 % (p=0.039). Das Gradientenmass war im Mittel um 4.2 %
(p<0.001) reduziert. Das fu¨hrte zu einer Dosisreduktion im umliegenden Gewebe, die
sich in einer Reduktion von V20Gy und V12.5Gy um 5.5 % (p=0.002) und 4.5 %
(p<0.001) zeigte. Diese dosimetrischen Verbesserungen konnten fu¨r den X10FFF Strahl
nicht beobachtet werden. Die Unterschiede in den Normalgewebsdosen waren fu¨r beide
FFF Strahlqualita¨ten statistisch nicht signifikant. Die mittlere Dauer der Bestrahlung
(Strahlzeit) war 111 s (2 SD = 11 s) fu¨r X10FFF, 128 s (2 SD = 19 s) fu¨r X6FFF,
und fu¨r X6FF Pla¨ne im Mittel 269 s (2 SD = 71 s). Die mittlere Dosisleistung betrug
1555 ± 264 MU/min bzw 1368 ± 63 MU/min, fu¨r X10FFF und X6FFF. Pla¨ne, die die
konventionelle X6 Strahlqualita¨t verwendeten, wurden immer mit maximaler Dosisrate
von 600 MU/min bestrahlt.
Innerhalb der Prostata Studie fand man keine Unterschiede zwischen den vier verwen-
deten Strahlqualita¨ten in Bezug auf PTV Abdeckung, Konformita¨t und Homogenita¨t.
Die mittlere Ko¨rperdosis und das Volumen des gesunden Gewebes, das mit 50% der
verschriebenen Dosis bestrahlt wird nahm mit zunehmender Energie energy ab (r2 =
0.8275, p <0.01). X6FFF deponierte 3.6% mehr Dosis im gesunden Gewebe im Ver-
gleich zu X6 (p <0.01). X10FFF deponierte 3.0% (p <0.01), und X10 5.8% (p <0.01)
weniger Dosis im gesunden Gewebe im Vergleich zu X6. Die mittlere Dosis zum Rek-
tum nahm signifikant zu im Vergleich zu X6 (2.6%, p <0.01). Die mittlere Dosis zur
Blase erho¨hte sich fu¨r X6FFF um 1.3% und reduzierte sich um 2.3% fu¨r X10FFF. Die
Benutzung eines einzelnen 360°Bestrahlungsbogen in Kombination mit FFF Strahlung
erho¨hte die Behandlungseffizienz um 35% (2 SD = 10%). Die X10FFF Strahlqualita¨t war
der beste Kompromiss zwischen einer niedrigen Gesamtko¨rperdosis und der Schonung
der Risikoorgane Rektum und Blase.
Abstract
The flattening filter has been an inherent part of a clinical medical accelerator since
the first application in 1953. It compensates the non-uniformity of the bremsstrahlung
photon fluence across the field and thus simplifies dose calculations and prediction of
dosimetric outcome when multiple fields are combined. With the introduction of modern
treatment planning techniques, such as intensity modulated radiation therapy (IMRT)
or volumetric modulated arc therapy (VMAT), that deliberately modify actual fluence
distributions to produce optimal fluence maps for each treatment field, the need to
flatten photon beams seems not to be absolutely necessary for these techniques. This
led to introduction of so called Flattening Filter Free (FFF) beams. In the scope of this
thesis, several specific areas have been investigated in order to asses the contribution of
FFF beams to clinical radiation therapy.
Dosimetric characteristics of a new linear accelerator (TrueBeam, Varian Medical Sys-
tems), designed to deliver flattened and FFF beams, was investigated. Dosimetric data
included depth dose curves, profiles, surface dose, penumbra, out-of-field dose, output,
total and scatter factors and were examined for conventional as well as FFF beams of
nominal energy 6 and 10 MV (X6, X6FFF, X10, and X10FFF). It was found that FFF
beams have lower mean energy (tissue-phantom ratio at the depths of 20 and 10 cm
(TPR 20/10): X6, 0.667; X6FFF, 0.631; X10, 0.738; X10FFF, 0.692); maximum dose
is located closer to the surface; and surface dose increases by 10 %. FFF profiles have
sharper but faster diverging penumbra. For small fields and shallow depths, dose outside
a field is lower for FFF beams; however, the advantage fades with increasing phantom
scatter. Output increases 2.26 times for X6FFF and 4.03 times for X10FFF and is less
variable with field size; collimator exchange effect is reduced.
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Accuracy of beam modelling under physical conditions using Anisotropic Analytical
Algorithm (AAA, Varian Medical Systems) was evaluated by comparing beam model
with measured dataset. Despite the fact that AAA has been simplified for FFF beams,
it was shown that FFF beams are modelled with the accuracy comparable to the one
known for conventional beams. These findings confirm the previous premise that the
absence of flattening filter could make modelling of FFF beams more straightforward
(less changes in the energy spectrum, reduction of extra-focal photons, etc.) Using γ-
analysis, criteria of 2 % depth-dose and 2-mm distance-to-agreement were always met.
The γ-analysis utilised a modified 1D γ-concept. The algorithm first performs a “local”
fit of the reference and the evaluated datasets. For a particular point on the fitted
evaluated curve, the γ-value is derived as the shortest distance between the point and
the fitted reference curve. This approach removes variations of the obtained γ-value
related to the discrete character and noise in the original datasets. Originally, this tool
has been developed to evaluate similarity of two sets of commissioning data. Thanks to
its universal character, it can serve as well for comparison of any kind of one-dimensional
dose distributions.
Commissioning measurements required a revision of dosimetric characteristics of ionisa-
tion chambers with respect to high dose rates of FFF beams (up to 24 Gy min−1). For
conventional beams, the ion collection efficiency of all air-vented ionization chambers
was above 0.995. For FFF beams, the collection efficiency of all examined air-vented
chambers was found sufficiently high to allow reliable assessment of relative dosimetry
and correction factors for absolute dosimetry were less than 1 % in all cases. However,
ion-collection efficiency was found to be insufficient for an iso-octane-filled ionisation
chamber when utilised for FFF beams and this chamber cannot be recommended for
relative dosimetry of these beams.
Radiobiological effects associated with FFF beams have been studied on two human
glioblastoma cell lines treated with doses up to 20 Gy and using different dose rates. Dose
verification was performed and colony formation assays were carried out. To compare
the predictability of our data, radiobiological models were included. It was found that
clonogenic survival was statistically reduced, if the total dose was delivered with a higher
dose per pulse while keeping the mean dose rate constant. It was further demonstrated
that X10FFF and X10 with the same dose per pulse do not exhibit difference in the
survival, hence the difference in the killing efficiency cannot be contributed to changes
in energy spectrum. Pulse repetition frequency did not influence the survival.
Treatment planning studies assessing the contribution of FFF beams to stereotactic
ablative radiotherapy of stage I non-small cell lung cancer and to localised prostate
radiation therapy have been carried out. Both studies showed that conventional and
FFF beams yield quantitatively comparable dose distributions and only minor dosimetric
differences were found. However, significant improvement in treatment delivery efficiency
was observed for FFF plans in both studies.
In case of the lung study, obtained dose distributions were conformal (CI<1.17) and ex-
hibited a steep dose fall-off outside the PTV. The ratio of monitor units for FFF versus
FF plans in the study ranged from 0.95 to 1.21 and from 0.93 to 1.25 for X6FFF/X6FF
and X10FFF/X6FF comparisons, respectively. Comparison of cumulative dose volume
histograms for a patient’s body showed that X6FFF plans exhibited improved confor-
mity and reduce the volume of tissue that received more than 50% of the prescription
dose. Parameters related to dose gradient showed statistically significant improvement.
CI50%, CI60%, CI80%, and CI100% were on average reduced by 4.6 % (p<0.001), 4.6 %
(p=0.002), 3.1 % (p=0.002), and 1.2 % (p=0.039), respectively. Gradient measure was
on average reduced by 4.2 % (p<0.001). Due to dose reduction in the surrounding lung
tissue, the V20Gy and V12.5Gy were reduced by 5.5 % (p=0.002) and 4.5 % (p<0.001).
These dosimetric improvements in the fall-off were not observed for the X10FFF plans.
Differences in sparing of other normal tissues were not found to be statistically signif-
icant for either of the two FFF beams. Mean beam-on times were 111 s (2 SD = 11
s) for X10FFF, 128 s (2 SD = 19 s) for X6FFF, and X6FF plans required on average
269 s (2 SD = 71 s). While the mean dose rate was 1555 ± 264 MU/min, 1368 ± 63
MU/min, for X10FFF and X6FFF, plans using the conventional X6FF were delivered
with the constant maximum dose rate of 600 MU/min.
In case of the prostate study, there were no difference detected between the four beams
in PTV coverage, conformity, and homogeneity. Mean body dose and body volume
receiving 50% of the prescribed dose decreased with increasing mean energy (r2 = 0.8275,
p <0.01). X6FFF delivered 3.6% more dose compared with the X6 (p <0.01). X10FFF
delivered 3.0% (p <0.01), and the X10 5.8% (p <0.01) less mean body dose compared
with X6. There was a significant increase in the mean dose to the rectum for the X10
compared with X6 (2.6%, p <0.01). Mean dose to the bladder increased by 1.3% for
X6FFF and decreased by 2.3% for X10FFF. Using a single arc and FFF, treatment time
was reduced by 35% (2 SD = 10%). X10FFF beam provided the best solution, sparing
rectum and bladder and minimizing whole-body dose.
Chapter 1
Introduction
1.1 Cancer in Europe
Noncommunicable diseases - such as cardiovascular diseases, cancer, and chronic obstruc-
tive pulmonary disease - account for 80 % of deaths in the European region. Diseases
of the circulatory system (ischaemic heart disease, stroke, etc.) are the most important
cause of premature death (before the age of 65), accounting for nearly 50 % of the total.
Cancer is the second leading cause, accounting for nearly 20 %. However, with the aging
population, the risk of cancer is rising. Currently, cancer is the main cause of premature
death in 28 of the 53 countries in the region, and is predicted to further increase by
2020 [3].
The latest provisional information for the 27 member countries of the European Com-
munity (EU-27) relating to causes of death shows that cancer was a major cause of
death in the region - averaging 166.9 deaths per 100 000 inhabitants across the EU-27
in 2010 [4].
There were an estimated 3.45 million new cases of cancer (excluding non-melanoma skin
cancer) and 1.75 million deaths from cancer in Europe in 2012. The most common
cancer sites were cancers of the female breast, followed by colorectal, prostate and lung.
These four cancers represent half of the overall burden of cancer in Europe. The most
common causes of death from cancer were cancers of the lung, colorectal, breast and
stomach [4].
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1.2 Role of radiation therapy
The major treatment modalities for cancer are surgery, radiotherapy and systemic ther-
apy (chemotherapy). Their selection is based on evidence of the best existing treatment
given the resources available. They may be used alone or in a combination. Surgery
alone is only likely to be highly successful when the tumour is localised and small in
size. Chemotherapy alone can be effective for a small number of cancers, such as haema-
tological neoplasms (leukaemias and lymphomas), which can generally be considered to
be widespread from the outset. Combined modality therapy requires close collaboration
among the entire cancer care team. Despite that radiotherapy utilisation rates for can-
cer may vary widely internationally, it is estimated that approximately 50 % of cancer
patients should receive radiation [5].
1.3 Brief history of megavoltage radiation therapy
The generation and transmission of radiation in the clinical environment depends on very
sophisticated technology. Up to the 1950’s, most of the external beam radiotherapy
was carried out with x-rays generated at voltages up to 300 kV. In the 1950’s and
1960’s, they were gradually replaced by development of high-energy machines and by
the increasingly more popular cobalt-60 units. Radiotherapy utilising these machines is
referred to as megavoltage radiation therapy despite the fact that strictly speaking the
term megavoltage should be reserved only to x-ray beams of energy higher than 1 MV
(hence excluding γ-rays). The shift from kilovoltage into megavoltage radiation therapy
was accompanied by an improvement in overall five years survival from 39% in the 1960’s
to 50% in the 1980’s took place [6]. Betatrons were used for radiotherapy in the early
1950’s. They preceded the introduction of linear accelerators by several years. Operation
of the betatron is based on the principle that an electron in a changing magnetic field
experiences acceleration in a circular orbit. Although the betatrons can provide x-ray
and electron therapy beams over a wide range of energies, from less than 6 MeV to more
than 40 MeV, they have low electron current, and the x-ray dose rates and field size
capabilities are low compared with linear accelerators or modern cobalt units. However,
their beam current is adequate to provide a high dose rate for electron therapy mode.
The reason for this difference is that the x-ray production via bremsstrahlung is relatively
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inefficient and requires much higher primary electron beam current (about 1000 times).
Linear accelerators (Linac) are technologically more advanced and their development
evolved with the earlier advent of the microwave power tube such as the klystron that
was developed during the World War II (source of microwave power for radars). Linacs
use the high-frequency electromagnetic waves to accelerate charged electrons to high
energies at they pass through a linear tube. Linac-based radiation therapy for cancer
treatment began with treatment of the first patient in 1953 in London at Hammersmith
Hospital, with an 8 MV machine built by Metropolitan-Vickers [1]. A short while later
(1955), the first patient was treated with 6MV photons generated by a Linac in Stanford
Hospital in San Francisco.
The earlier Linacs were limited by their inability to rotate around the patient. The first
360 degree isocentric Linac was developed in 1960 at Varian Medical Systems Inc (Palo
Alto) and transported to University of California Los Angeles (UCLA). In the following
years, further technological improvements made it possible to reduce Linac’s complexity,
reduce its cost, and to extend its versatility (electron/photon treatment mode, multiple
energies, etc.) Linacs became gradually more popular and today they deliver the major-
ity of radiation therapy in developed countries. In 2004, linear accelerators comprised
88 percent of treatment courses in the USA. [7]
The role of the Cobalt-60 unit has been largely taken over by the linear accelerator.
The major limitations of the Cobalt-60 units are their low energy (1.17 and 1.33 MeV),
lower output that further reduces with the decay of the source and necessitates replace-
ment of the source every 5-7 years, and wider penumbra given by the finite size of the
source. Also, disposal of spent source represents a problem. Meanwhile, whilst linear
accelerator technology has experienced substantial developments over the intervening
years, modernisation of the cobalt-60 units has been marginal. Despite these draw-
backs, cobalt-60 units are still widespread especially in developing countries, since the
machinery is relatively reliable and simple to maintain compared to the modern linear
accelerator. However, the cobalt-60 plays useful role in specialised applications, such as
the Leksell gamma knife.
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1.4 Linac design
The general principle of operation of a typical medical linear accelerator can be sum-
marised as follows (figure 1.1): a modulator provides high voltage pulses of microseconds
duration. These pulses are delivered simultaneously to the electron gun and to mag-
netron or klystron - devices for producing microwaves. Pulsed microwaves are injected
into the evacuated structure (tube) via a waveguide system. At the proper moment,
electrons produced by an electron gun are also pulse injected into the accelerator struc-
ture. Injected electrons are accelerated either by stationary or travelling microwaves
depending on the design of the accelerator’s waveguide.
Figure 1.1: Schematic diagram of a medical accelerator (reproduced from [6]).
Magnetron functions as high-power oscillator, generating 3GHz microwave pulses of
several microseconds duration and with repetition rate of several hundred pulses per
second. Whereas the klystron acts as a microwave amplifier. It needs to be driven by a
low-power microwave generator. Whereas magnetrons are less expensive, klystrons have
longer time span, and are able of delivering higher power levels and are preferred for the
beam energy above 20 MeV [8].
As high-energy electrons emerge from the exit window of the accelerator structure, they
are in the form of a narrow pencil beam. Linacs providing energies up to 6 MeV have
relatively short accelerator tubes, allowing electrons to proceed on a straight trajectory
into the treatment head. In the higher energies Linacs, a longer accelerator tube is
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typically placed perpendicularly to the treatment head axis and electrons are deflected
by 90 (or 270) degrees using bending magnets.
The final part of a Linac is called treatment head. It consists of a target, scatter foil,
primary and secondary collimating system, flattening filter, monitor ionisation chambers,
and in some cases additional beam modifying devices.
Modern linear accelerators offer both x-ray and electron treatment modalities. Brems-
strahlung photons are produced when accelerated electrons impinge on a target of a high
proton number material. The target is water-cooled and is thick enough to absorb most
of the incident electrons. Bremsstrahlung photons are characterised by a continuous
spectrum of energies with the maximum energy equal to the energy of incident electrons.
The average energy of the photons is approximately one third of the maximum energy.
For the electron treatment modality, accelerated electrons strike on a thin scattering foil.
The foil ensures that most electrons are scattered instead of undergoing bremsstrahlung,
hence a broad electron beam with uniform fluence is obtained from the original pencil
beam.
The primary collimator is a shell around the treatment beam made of high-density
shielding material such as lead-tungsten alloy. It provides sufficient shielding against
leakage radiation and is the first definition layer for the therapeutic beam collimator.
Megavoltage bremsstrahlung has a strongly forward peaked distribution of intensity, i.e.
most of the photons have a similar trajectory as the electrons impinging on the target.
In order to make the beam intensity uniform (over a certain field width), the resultant
bremsstrahlung beam passes through a flattening filter. The filter is conical in shape
and is made of a combination of materials of different proton number. For each photon
energy, a linac uses a dedicated flattening filter.
The flattened x-ray beam further passes through monitor ionisation chambers, typically
transmission chambers, i.e. plan-parallel chambers with a diameter greater than the
beam’s cross-section. The main function of the monitor chambers is to control the
instantaneous dose rate, accumulated dose, and beam’s flatness and symmetry.
The secondary collimation consists of two pairs of movable jaws, made of lead or tung-
sten, which allow to collimate of the beam to rectangular fields of any size between 0 x
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0 cm2 and 400 x 400 cm2. Finally, a photon beam can be additionally modified using
devices such as multi-leaf collimator (MLC), wedges, blocks, compensators, etc.
1.5 Flattening filter
The flattening filter has been an inherent part of a clinical medical accelerator since
the first application in 1953 [1, 2] (figure 1.2), and it used to compensate for the non-
uniformity of the bremsstrahlung photon fluence across the field, which helped to simplify
dose calculations. It should be noted that first computer-based treatment planning
systems allowing a three-dimensional calculation of dose distribution appeared several
decades later.
However, there are also trade-offs associated with the use of the flattening filter. Ar-
guably the most important one is related to the reduction of output (dose rate) due to
beam attenuation in the material of a flattening filter. One of the first references to the
use of unflattened photon beams appears in 1991, reporting the properties of radiosur-
gical beams from a 6 MV Therac accelerator (Atomic Energy of Canada, Ltd) without
the flattening filter [9]. The investigated application was limited to circular fields of size
up to 3 cm in diameter, where the change in intensity across an unflattened beam is
not pronounced. In this work, the authors were motivated by the need to reduce treat-
ment delivery time of radiosurgery. In 1993, the concept of tomotherapy, a dedicated
machine that delivers treatment in slices was introduced. This machine also utilises an
unflattened beam and further beam modulation is achieved with a dedicated multileaf
collimator [10].
Various Monte Carlo studies have shown that the flattening filter is responsible for the
majority of scatter produced in the treatment head [11, 12], causes changes in beam
quality away from the central axis [13] and acts as the main source of electron contam-
ination [14–16]. Other Monte Carlo studies investigate various properties of flattening
filter free (FFF) beams using commercially available Linacs, where a flattening filter was
removed for the purposes of modelling [17–21]. There were also analogical dosimetric
measurements performed with dedicated experimental machines or prototype linear ac-
celerators without a flattening filter [22–25] and some preliminary treatment planning
studies were performed for these prototypes [26].
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Figure 1.2: Cross-section of x-ray head of historically first clinically used linear ac-
celerator as depicted in [1]. Note the flattening filter (12).
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In the last two decades, radiation therapy underwent substantial development in optimi-
sation of treatment planning. Modern treatment planning techniques, such as intensity
modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT),
use multileaf collimators to deliberately modify actual fluence distributions to produce
optimal fluence maps for each treatment field. Clinical experience shows that fluence
maps can exhibit a high degree of complexity. In this context, the necessity to flatten
photon beams seems not to be absolutely necessary for these techniques. Instead, the
leaf sequences can be adjusted accordingly to take into account the non-flat profile of
FFF beams.
1.6 Motivation
Vendors producing linear accelerators have reacted to these developments in radiation
therapy. As an example, Varian Medical Systems introduced a dedicated C-arm Linac,
TrueBeam, designed to deliver both flattened and FFF photon beams. The prototype
of this accelerator was installed at University Hospital Zu¨rich and Memorial Sloan-
Kettering Cancer Centre. In the scope of this collaboration, the system was optimised
and prepared for clinical application. Among other tasks, this mainly involved an assess-
ment of basic dosimetric properties of FFF beams, investigating behaviour of available
detectors, evaluation of radiobiological impact, and performing of comparative treatment
planning studies in clinically relevant conditions.
University Hospital Zu¨rich was the first clinic worldwide to use TrueBeam clinically
utilising both conventional as well as FFF beams.
1.7 Outline of the thesis
In chapter 2, a modified concept for γ-analysis for a comparison of dose profiles is
introduced. Originally, this tool has been developed to evaluate similarity of two sets
of commissioning data. Thanks to its generality, it can serve as well for comparison
of measured and modelled data as later demonstrated in chapter 3, and can be used
for any kind of one-dimensional dose distribution. It has been even successfully applied
for the verification of an agreement between measured and modelled depth dose curves
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of proton beams (between energies 70 and 230 MeV). I developed the algorithm for
the one-dimensional γ-analysis, acquired the necessary dosimetric data, performed the
analysis, and have written the manuscript [27] presented in chapter 2.
Chapter 3 represents a dosimetric comparison of conventional and FFF beams from the
TrueBeam linear accelerator and assesses the accuracy of beam modelling in a treatment
planning system (Eclipse, Varian Medical Systems). Measurements were designed and
led by myself. The execution of the measurements was done by myself and Stephanie
Lang. The manuscript [28] was written by myself.
Chapter 4 deals with one of the dosimetric aspects encountered with FFF beams. These
beams exhibit high dose rates which might influence the performance of some ioni-
sation chambers (due to their lower ion collection efficiency). This study evaluates
the suitability of several commercially available ionisation chambers for measurements
in FFF beams. I have contributed to measurements and to the preparation of the
manuscript [29].
The Clinic for Radiation Oncology of the University hospital Zu¨rich has performed a
radiobiological study examining the influence of high dose rates of FFF beams on cancer
cell survival. I have contributed to address the dosimetric aspects of the study and
supported the irradiation of samples. The published study [30] is presented in chapter
5.
Chapter 6 evaluates the utilisation of FFF beams for stereotactic ablative radiotherapy
of stage I non-small cell lung cancer. The study was designed and the manuscript [31]
has been written by myself. The manuscript was accepted for publication in Medical
Physics and is currently prepared for publishing.
Another treatment planning study evaluating the contribution of FFF beams to localised
prostate radiation therapy is presented in chapter 7. I have contributed to treatment
planning and the data analysis. The study was published as a manuscript [32].
Chapter 2
Quantitative evaluation of a
beam-matching procedure using
one-dimensional γ-analysis1
2.1 Introduction
Many radiation therapy centres have more than one linear accelerator at their disposal.
For these centers, vendors offer “beam matching” as a part of their contract. In this
approach, treatment beams of the unit being installed are tuned in such a way that
the dosimetric characteristics meet reference values within a specified interval. If all
machines in the department have been tuned to these values, they are implicitly tuned
to each other. When installing the reference unit, an extensive set of dosimetric data has
to be gathered in order to properly commission it and to obtain all beam data needed for
beam modelling in a treatment planning system. Beam matching significantly reduces
the dosimetrical workload during commissioning. Instead of measuring the full set of
dosimetric data, only a set of cross-check measurements is needed to investigate the
agreement of subsequently installed units with the reference beams. If the reference and
matched beams are shown to be identical within a certain level of tolerance, no further
measurements need to be carried out. The beam data gathered for the reference unit
1This chapter has been published as a manuscript [27]: J. Hrbacek, T. Depuydt, A. Nulens, A.
Swinnen, and F. Van den Heuvel, “Quantitative evaluation of a beam-matching procedure using one-
dimensional gamma analysis,” Medical physics, vol. 34, p. 2917, 2007.
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can then be used to commission the other units. Moreover, having units with matched
beams enables increased flexibility in clinical work. If one of the matched units is down,
any of the others can take over its patient load without the necessity of re-planning.
As early as in the 1990s, several scientific articles evaluating dosimetric performance of
Varian’s Clinacs 600C and 2100C (Varian Medical Systems, Inc., Palo Alto, CA) were
published [33,34]. These articles confirm good agreement of photon beam characteristics
of alike accelerators. Marshall and colleagues [34] showed satisfactory agreement of 6
MV beams of two dissimilar Varian machines after customisation of a flattening filter.
To our knowledge, there is no recent study on this topic. Also, we have not found any
evidence concerning the matching of electron beams. The published articles as well
as comparison of dosimetric parameters in the beam matching acceptance procedure
defined by the vendor is based on relative measurements at predefined points under
specific geometry. In this article, we have implemented a one-dimensional (1D) γ-index
that enables to evaluate the level of agreement of matched beams over entire profiles or
depth dose curves.
2.2 Material and methods
Varian (Varian Medical Systems, Inc., Palo Alto, CA) offers two types of beam match-
ing, a “basic” and a “fine” one. In this work we will solely concentrate on the matching
termed as fine. The beam matching acceptance criteria are based on a depth ionisa-
tion curve as well as transverse, radial, and diagonal profiles measured at the vendor’s
prescribed geometry. The vendor does not use the entire curve to evaluate a quality of
beam matching. Instead, only some points of a curve are used for this purpose. In case
of a photon depth ionisation curve, the location of depth of maximum ionisation and
relative ionisation at a depth of 10 cm is used. For electron depth ionisation curves,
points of 90 %, 80 %, and 50 % relative ionisation are used. According to the vendor’s
procedure, for photon and electron profiles, the relative ionisation at any point within
the central 80 % of a scan should meet prescribed criteria. However, only six points from
this region are effectively investigated. A limited overview of the fine beam matching
procedure as defined by the vendor is given later.
Chapter 2: One-dimensional γ-analysis 12
2.2.1 Beam matching criteria as defined by the vendor
For each measured parameter, an average value is calculated from the parameter’s values
of all matched units xi. The vendor’s acceptance criteria ∆ are all related to the average
x¯ and define the interval around the average into which all xi have to belong. This
approach enables to match a group of more than two treatment units
|xi − x¯|<∆, ∀xi (2.1)
2.2.1.1 Depth profiles
The depth of maximum dose along the central axis shall be within ±1.5 mm of the
average. The relative dose at 10 cm depth on the central axis shall be within ±10 %
of the average for basic matching and ±0.5 % in the case of fine beam matching. For
electron beams, a position of 90%, 80%, and 50% relative ionisation should be within
±1 mm of the reference value.
2.2.1.2 Transversal profiles (photons)
For photon profile measurements, the dose at any point within the central 80% of the
radial and transverse axis, normalised to the central axis measured at a depth of 10 cm
in water shall be within ±2% of the average of the measured values at that point. This
test is performed for 40 x 40 cm2 and 10 x 10 cm2 field sizes. The maximum dose in the
plane perpendicular to the beam axis at the depth of maximum dose in water shall be
within ±1% of the average.
2.2.1.3 Transversal profiles (electrons)
For electron beams, the ionisation within 80% of the diagonal scans, normalised to the
central axis, measured at the depth of maximum dose shall be within ±2% of the average
of the measured values at that point. This test is performed for the applicators 25 x
25 cm2 and 10 x 10 cm2 with standard insets. If only a pair of treatment units is
compared (the reference one and the tuned one as was the case in our department),
it is more comprehensive to restate the criteria as the maximum allowable difference
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in measurement of a dosimetrical parameter for the two units (xR,xT ) rather than the
difference between the value of a tuned unit and the average
x¯ =
xR + xT
2
, (2.2)
|xT − x¯| = xR + xT
2
<∆, (2.3)
|xT − xR|<2∆, (2.4)
As seen from 2.4 the maximum allowable difference in the estimate of the parameter for
the two compared units can be expressed as two times the vendor’s criteria. For instance,
if the vendor requires the depth of maximum dose along the central axis to be within±1.5
mm of the average, the difference in the parameter’s value between the reference and
the tuned unit can be up to ±3 mm and still pass the match criterion. We consider the
vendor’s criteria rather loose and arbitrary to guarantee full interchangeability of beams
in clinical practice. In the least favourable instance of beam matching, a significant
systematical error would be introduced in the dosimetric chain. The borderline cases of
beam matching are suitable for an emergency single fraction irradiation in a fractionated
treatment, when an unexpected failure of a treatment unit occurs. However, we find it
unacceptable to conceptually alternate units in this case without recalculating the dose
distribution.
2.2.2 Measurements
As the evaluation of beam matching is performed during the acceptance test of a new unit
with a set of measurements prescribed by the vendor, it was our concern to investigate
the level of agreement of matched beams for commissioning measurements as they are
more closely related to clinical dosimetry. Therapeutic beams of Varian Clinac 2100
C/D serial No. 3065 were compared with corresponding matched beams of Varian
Clinac 2100 C/D serial No. 3170. Both accelerators have two photon beams of nominal
energies of 6 and 10 MV and five electron beams with respective energies of 6, 9, 12, 16,
and 20 MeV. The second unit was installed in our department approximately 6 months
after the first one. The performed dosimetric measurements consist of point relative
measurements and profile relative measurements. The same dosimetric equipment was
used for the measurements of both treatment units. For point measurements, a CC13
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chamber (Scanditronix-Wellhofer) has been utilised with Keithley 35040 electrometer.
Profile measurements were carried out using the Scanditronix-Wellhofer Blue Phantom
controlled by OmniPro Accept 6.1 software. A pair of CC13 ionisation chambers was
connected to a dual processor based control unit CU 500-E (Scanditronix-Wellhofer).
For electron depth ionisation curves, the field CC13 chamber was replaced with a NACP-
02 ionisation chamber (Scanditronix-Wellhofer). The measured ionisation curves were
converted to dose curves using the NACP formalism implemented in OmniPro software
[35]. When scanning dose profiles, spacing between points of a profile is set by the
software according to selected speed of the movement of the field detector. Due to the
number of profiles needed, we chose a medium speed with a spacing of 0.4 mm.
2.2.2.1 Point measurements
• Output factors for 6 and 10 MV for selected field sizes including the smallest (3
x 3 cm2), the largest (40 x 40 cm2), and the most asymmetrical field size possible
(3 x 40 cm2),
• Quality index for 6 and 10 MV,
• MLC transmission for 6 and 10 MV,
• Block transmission for 6 and 10 MV,
• Tray transmission for 6 and 10 MV,
• Wedge factor for all hard wedges for 6 and 10 MV,
• Output factors for all hard wedges for 6 and 10 MV,
• Quality index for wedged fields 6 and 10 MV,
• Wedge factors for enhanced dynamic wedges for 6 and 10 MV were compared with
a theoretical value calculated according to a formula provided by the vendor [36].
2.2.2.2 Profile measurements
• Depth dose curves for both photon beams with field sizes 3 x 3 cm2,10 x 10 cm2,
and 40 x 40 cm2,
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• Depth dose curves for both photon beams and all hard wedges with field sizes 3 x
3 cm2,10 x 10 cm2, and 20(15) x 40 cm2,
• Depth ionisation curves for all electron beams and all applicators (including no
applicator option) with standard insets,
• Transversal/radial profiles for both photon beams with field sizes 3 x 3 cm2,10 x
10 cm2, and 40 x 40 cm2, at depths of dmax, 5, 10, 20, and 30 cm,
• Transversal/radial profiles for both photon beams and all hard wedges with field
sizes 3 x 3 cm2 , 10 x 10 cm2, and 40 x 40 cm2, at depths of dmax, 10, and 30 cm,
• Transversal/radial profiles for all electron beams for applicator 25 x 25 at Varian
recommended depth for all electron beams, and
• A profile in air for all electron beams required for commissioning of Varian’s elec-
tron Monte Carlo algorithm [37,38].
2.2.3 Algorithm for γ-index calculation
The γ-index is a mathematical concept that enables a quantitative comparison of two
dose distributions. In principle, γ-evaluation can compare a pair of dose distributions of
any number of dimensions. For instance, it has been employed in a verification of two-
dimensional (2D) and three-dimensional dose distributions measured by gel dosimetry
or for quality assurance of 2D fluence maps of intensity modulated radiation therapy
(IMRT) fields [39]. A description of the γ-index may be found in an article by Low [40].
In the present work, we have used it to evaluate the agreement between dose profiles
(i.e., of 1D distribution) of two treatment units with matched beams.
When performing the γ-evaluation, one distribution is referred to as the reference and
the other as the evaluated. The γ-index is calculated independently for each data point
of the reference distribution using the entire evaluated distribution. In general, the
γ-evaluation is not symmetric with respect to the two distributions. If the two distri-
butions are qualitatively different (for example a smooth analytically calculated dose
distribution and a measured dose distribution with the presence of noise), care should
be taken to decide which of the two distributions should be treated as reference and
which as evaluated [41].
In our case, both distributions (dose profiles) are qualitatively the same. They represent
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water phantom measurements for two different treatment units at different times. They
were performed in the same manner, using the same equipment and the same setup.
To us it seemed most natural to exchange the terms “evaluated” and “reference” dis-
tribution, so that for a particular point to be evaluated the closest of the points of the
reference data set is sought. The new treatment unit profiles were chosen to be the
evaluated and the profiles of the previously installed unit the reference.
A dose profile is a set of values that represent the ratio of the field-to-reference detector
readings to a predetermined point at discrete (usually equidistantly spaced) points in a
given scan direction. These measurements are subject to the introduction of stochas-
tic noise. As Low has demonstrated, the discrete character of data perturbs the γ-
evaluation [41]. Low concludes that the pixel spacing of the evaluated distribution
needs to be sufficiently small to provide an accurate calculation of γ in regions of steep
dose gradient. By histogram analysis he also demonstrates significant perturbations in
the presence of noise. Introduction of noise in the evaluated distribution reduces the
average value of γ. On the other hand, if the reference distribution is noisy, the av-
erage value of γ is accurately calculated, but there are great point to point variations
in the γ-distribution. As a one-dimensional γ-evaluation does not require an extensive
calculation time, we have decided to use a more sophisticated approach to calculate γ
to overcome both limitations.
In the case of 1D γ-evaluation, the γ-index is the shortest distance between a refer-
ence point and any point of the evaluated dataset in a position-to-dose graph which has
the axes normalised to distance-to-agreement (DTA) and dose difference (DD) criteria.
Here, rather strict criteria of 1 mm DTA and 1% DD have been set for the evaluation
of matched beams.
Our algorithm first performs a “local” a fit of both datasets. Points of each dataset that
occur in the proximity of the reference point are fitted using a second order polynomial.
This way two polynomials are obtained, each locally describing one of the profiles.Local
in this sense means that only points of a profile within a certain region around the ref-
erence point are taken into account for the fit.
For this purpose a radial magnitude of 3 around the reference point in the normalised
distance-to-dose space has been chosen. As changes in dose easily reach 10% per mm or
more in some parts of a profile (such as the penumbra), the dose normalised to DD was
reduced by a factor of 10. The proximity region shall be therefore considered to be an
ellipse around the reference point having the major axes parallel with the dose axes.
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The size of the proximity region was determined using the most complex profiles (pro-
files of the largest hard wedge in the direction of the gradient). The proximity region
was gradually increased and after each increase, all fits on a profile were graphically
visualised allowing us to make sure that data points were fit adequately. The chosen
size of proximity region ensures good conditioning of the fitted polynomials as well as
suitability of the chosen fitting function. Of course, if the region of proximity is enlarged,
more data points are used to define the fitted polynomial and the resulting γ-profile gets
smoother.
However, the size of the region cannot be enlarged arbitrarily. If the region is too large,
some deformations of γ-profile occur due to the fact that the second order polynomial
is not an adequate fit for some parts of the profile.
We have observed that it would be possible to further enlarge the proximity region and
still obtain a suitable fit of the data points. Nevertheless, this did not improve the
γ-profiles significantly. If the proximity region is too small, there might not be enough
points within the region of proximity for the polynomial fit and the γ-value cannot be
determined. It might also occur that the closest point to the evaluated point lies out-
side of the region. In this situation the γ-value will be overestimated. The higher the
dissimilarity between the compared profiles, the larger the proximity region needs to be.
For the chosen size of the proximity region used in this analysis, these effects would
occur for γ > 3 and therefore are not disturbing this analysis.
The reference point with coordinates (xR, yR) is projected onto the reference polynomial
curve. Instead of calculating γ for the point itself, γ is calculated for the projected value
(xR, yRP ). This way, noise in the reference profile is reduced.
As a final step, the γ-value is obtained by finding the minimal distance between the
projected value (xR, yRP ) and the polynomial fit of the evaluated dataset (described by
the quadratic equation y = a0 + a1x + a2x
2). Expressing the square of distance and
substituting the polynomial fit formula, the coordinates of the point (x , y) with the
minimum distance from (xR, yRP ) is sought using
∂r2
∂x
= 2(x− x0) + 1(a0 + a1x+ a2x2 − y0)(a1 + 2a2x) = 0. (2.5)
This approach supresses perturbations related to the discrete character of the original
dataset. By using the polynomial fit, the noise in the evaluated dataset is also reduced.
The algorithm is graphically interpreted in figure 2.1.
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Figure 2.1: Graphical representation of the γ-evaluation algorithm. For a point of
the evaluated dataset, the ellipse defines the proximity of the point (d). All points
inside the proximity ellipse are used to construct polynomial fit of both datasets (c).
The evaluated point is projected onto the local fit of the evaluated dataset (a). For
the projection of the evaluated point, the closest point on the local fit of the reference
dataset is sought (b). The γ-vector represents the shortest distance between the point
and the curve. In this case, γ = 1.1 is demonstrated. The black circle represents the
boundary of γ 6 1.
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2.2.4 Processing of the scanned profiles
The acquired relative dose profiles need to be normalised prior to their further eval-
uation. Dose profiles were arbitrarily normalised to the central axis, while the depth
ionisation curves are normalised to their maximum. The γ is calculated for all pixels of
the evaluated profile. The resulting set of γ-values is referred to as the γ-profile. We
also define γmax as the maximum value of the γ-profile.
To reduce inaccuracies in the positioning of the detector, all measured profiles were re-
centered based on the position of 50% isodose using the OmniPro software. However, we
have observed that this approach does not always provide the best alignment of profiles.
Therefore, a new strategy was implemented to center the profiles.
After precentering using the OmniPro software function, one of the paired profiles was
shifted -1.2, -0.9, -0.6, -0.3, 0, 0.3, 0.6, 0.9, and 1.2 mm relative to the other. (The
magnitude of the positioning correction roughly corresponds with the precision of detec-
tor positioning in a water phantom.) For every new position, the displaced profile was
renormalized to the new point corresponding to the central axis. For every cross-position
of the profiles, we calculated γ-profiles, yielding nine profiles, from which the smallest
γmax was selected.
However, we did not apply this approach to (photon and electron) depth dose curves as
the real discrepancies between profiles caused due to the difference of the mean energy
of the two beams could undesirably be compensated.
2.3 Results
2.3.1 Point measurements
Relative point measurements are summarised in tables 2.1,2.2,2.3. For 6 MV all differ-
ences between the point parameters of the two units are within -0.62 % and +0.56 %.
Similarly, for 10 MV the differences are within -0.29 % and +0.43 %.
2.3.2 Dose profile measurements
Out of the total of 170 profiles the 65 depth dose profiles were not subjected to the
cross-positioning procedure as described earlier. In 38 of the 105 remaining cases, the
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correction did not improve the γ-evaluation. A shift of 0.3, 0.6, 0.9, and 1.2 mm was
needed for, respectively, 38, 17, 7, and 5 profiles. 119 (or 70%) of the profiles had a
γmax < 1. These profiles met the chosen criteria of 1 mm DTA and 1% DD of local dose
in all pixels of a profile. The remaining 51 profiles include some pixels that fail these
criteria. The median of γmax was 0.86, a value of 80% and 90% percentile is 1.14 and
1.26, respectively. The greatest obtained value of γmax was 1.70.
2.4 Discussion
2.4.1 Detailed analysis
2.4.1.1 Depth dose curves in the proximity of the water level
In case of 13 profiles, we have observed a weak transgression (e.g., 1 < γ < 1.3) of
our criterion in the first few pixels of a depth dose curve and agreement in the rest of
the profile. These discrepancies are related to difficulties of dose measurement in the
buildup region rather than the beam characteristics.
2.4.1.2 Low signal
In five profiles, a discrepancy in the low dose region was observed when measuring at
the largest depth (figure 2.2). This effect is likely caused by variations in the base level
(zeroing the detector). During the commissioning of the reference treatment unit an
extensive number of scans was performed (including scans necessary for other treatment
planning systems) and it is very likely that despite careful handling of the measurements,
there are a few that were measured with the detector operating in a non-optimal range.
In the higher dose region the agreement is very good.
2.4.1.3 Electron profiles
Crossline or inline profiles of electron fields (ten in total) exhibit the same characteristics.
These scans were performed for the largest applicator (25 x 25 cm2) using the standard
insert. The level of agreement of the beams in the high dose region is very good, however,
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the new treatment unit exhibits a slightly sharper penumbra (figure 2.3). This effect
could be related to a small size discrepancy of the electron insets as well as a slightly
different level of scatter. From a practical point of view, these discrepancies do not seem
to be significant.
2.4.1.4 Wedged profiles
For seven wedged profiles, the infringement of γ = 1 criterion was found at the wedge’s
toe, i.e., around the point of highest dose of a wedged profile (figure 2.4). The dose
profile in this region is rather complex especially for larger wedges. An additional set of
measurements was performed to eliminate physical differences between the hard wedges
of the same nominal angle used in both machines. Profiles for the different wedges placed
in the same beam were compared. A very good agreement was observed and the hard
wedges can be considered identical.
We have observed that this type of profile is sensitive to cross-positioning of profiles. As
such, a significant increase of γ in this region is observed if the profiles are not properly
aligned. As the failure of γ analysis occurs randomly (i.e., not related to certain wedge
angle, field size, or depth of measurement), we consider that this effect is linked to the
measurement uncertainty rather than to a difference in the beam characteristics.
2.4.1.5 Photon depth dose curves
In the depth dose curves for 10MV photons using hard wedges, nominal angles of 45°and
60°and the smallest field size (e.g., 3 x 3 cm2), a consistent increase of γ is observed
with enlarging depth (figure 2.5). This effect is more pronounced for the latter hard
wedge. The discrepancies likely originate from a difference in the low energetic part of
a spectrum (different level of beam hardening). For thinner wedges and for any wedge
with a larger field size, this effect diminishes, whilst all other depth ionisation curves
completely pass the chosen γ-evaluation criteria. An additional factor is the possible
loss of electronic equilibrium in the measurement of this particular depth dose.
Chapter 2: One-dimensional γ-analysis 22
2.4.1.6 Solitary peaks
The remaining 12 profiles cannot be systematically classified. They exhibit solitary small
peaks (with γmax up to 1.20) that occur at random locations in a profile. The peaks have
a local character and affect only several subsequent pixels of the profile. The excesses
are attributed to residual noise in both profiles not fully suppressed by our analytical
γ-evaluation algorithm.
2.4.2 General discussion
The results show that the beam matching procedure can attain the chosen criteria of
1 % DD and 1 mm DTA. Out of all profiles, 70 % pass the criteria. The analysis of
remaining 30 % of profiles demonstrates that it is mainly the imperfections of measure-
ment that are the limiting factor better correlations. It is only the ten inplane and
crossplane profiles of electron beams and three photon depth dose curve profiles where
a γ > 1 has been shown conclusively. On the level of gamma analysis there is no dif-
ference between comparing depth dose curves or profiles. Indeed, the gamma analysis
just provides a number. However, the way the outcome is analysed does depend on the
type of curve. Transversal curves have five specific parts (high dose region, two penum-
bras, and two scattered dose regions), whereas depth dose curves essentially consist of
two parts: buildup and tail. For electrons a third part is of importance which is the
bremsstrahlung tail. Each part of the profile includes a different number of points and
has its local specifics. For example, depth dose curves will typically fail the criteria of
the gamma evaluation in the proximity of the water level, whereas the rest of the curve
exhibits good agreement.
The handling of the acquired profiles as demonstrated in this article goes beyond the
common practice in most radiation therapy departments. Our results show a slight
degradation of the γ-evaluation when cross-positioning optimisation is omitted. Despite
this all profiles have γmax < 2. As pointed out in the results section only five profiles
out of 107 needed a shift of 1.2 mm. This is of the order of the accuracy with which the
measurements were taken, using a 3 mm radius sized cylindrical chambers positioned
with 1 mm thick positioning lasers.
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Table 2.2: Percentage deviation of output factors 6 MV
Field size (cm) 3 5 10 20 40
3 +0.51 +0.37 +0.29 +0.23 +0.55
5 +0.23 +0.24 +0.08 +0.31 +0.14
10 -0.62 -0.05 0.00 +0.06 0.00
20 +0.07 +0.35 +0.27 -0.04 -0.16
40 +0.30 -0.05 +0.32 -0.13 -0.42
Table 2.3: Percentage deviation of output factors 10 MV
Field size (cm) 3 5 10 20 40
3 +0.17 +0.14 +0.12 +0.04 +0.32
5 +0.20 +0.13 0.10 +0.10 +0.11
10 -0.02 -0.18 0.00 -0.05 -0.08
20 -0.05 +0.05 -0.18 -0.14 -0.12
40 +0.04 +0.06 -0.19 -0.29 -0.30
The sample used for further commissioning of other machines was chosen in such a
way that for all modalities and energies the curves compared represented the reference
conditions and the extrema. For example, a 6 MV depth dose curve was compared for
field sizes 3 x 3,10 x 10, and 40 x 40 cm2. A profile for the same beam was measured at
the depth of maximal dose, 10 and 30 cm (the limit of our water tank). We do, however,
want to stress that when finding good accordance and when using the same model in
the planning system for the two machines, it is still necessary to perform spot checks to
ensure the correct behaviour of the planning system. All absolute values (output, tray
transmission, etc.) were always measured separately and entered in the planning system
for each machine.
2.5 Conclusion
Relative point and profile measurements have been performed to cross-check the validity
of Varian’s beam matching procedure. Matched beams, both photon and electron, show
very good level of agreement. 70% of profiles completely passes γ-evaluation with the
chosen criteria 1% DD and 1 mm DTA, 90% of profiles have their maximal γ-value
smaller than 1.26 (the highest γmax is 1.70).
In this particular case, the quality of the beam matching was very high and allowed
us to treat paired beams of both treatment units as identical and to use the beam
model of the reference treatment unit for the new unit. Nevertheless, it should be
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Figure 2.2: Example of a disagreement in the low dose region. The upper graph
shows reference and evaluated profile. The lower graph exhibits the γ-profile.
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Figure 2.3: Discrepancies in the penumbra region for electron fields. The upper graph
shows reference and evaluated profile. The lower graph exhibits the γ-profile.
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Figure 2.4: Discrepancies in the high dose region for wedged photon fields. The upper
graph shows reference and evaluated profile. The lower graph exhibits the γ-profile.
Chapter 2: One-dimensional γ-analysis 28
Figure 2.5: Depth dose curves for very small wedged photon fields at 10 MV. The
upper graph shows reference and evaluated profile. The lower graph exhibits the γ-
profile.
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noted that acceptance criteria of beam matching defined by the vendor are much more
benevolent. Therefore, although the acceptance criteria are met, the resulting quality of
beam matching does not allow full interchangeability of beams in the clinical practice.
For all practical purposes, based on the presented results, we suggest 2 mm DTA and
2% DD as a convenient criteria for γ-analysis to be met when evaluating the agreement
of profiles scanned in common dosimetrical conditions. Better results are attainable by
employing different strategies coping with the imperfections of measurements.
It is our opinion that matched beams which do not meet the earlier suggested criteria
should not be treated as clinically interchangeable.
Chapter 3
Commissioning of photon beams
of a flattening filter-free linear
accelerator and the accuracy of
beam modeling using an
anisotropic analytical algorithm1
3.1 Introduction
TrueBeam STx (Varian Medical Systems) is a new linear accelerator designed to deliver
flattened, as well as flattening filter free (FFF), beams. It represents a new platform
of Varian linear accelerators where many key elements, including the waveguide sys-
tem, carousel assembly, beam generation and monitoring control system, differ from the
preceding Clinac series. Based on our experience of commissioning the first clinically
used TrueBeam linear accelerator, we present a framework that summarizes dosimetric
characteristics of the new accelerator and compares our results with currently available
evidence on FFF technology.
1This chapter has been published as a manuscript [42]: J. Hrbacek, S. Lang, and S. Klo¨ck, “Com-
missioning of photon beams of a flattening filter-free linear accelerator and the accuracy of beam mod-
eling using an anisotropic analytical algorithm,” International Journal of Radiation Oncology* Biology*
Physics, vol. 80, no. 4, pp. 1228-1237, 2011.
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The interest in FFF technology results from the expectation that it will allow faster
treatment with reduced out-of-field dose as the flattening filter removal leads to an in-
crease of dose rate and a reduction of head scatter and leakage. FFF application is
foreseen primarily in stereotactic radiotherapy or hypofractionated treatments with an
escalation of dose per fraction. High dose rate could be advantageous for respiratory
gated or breath-hold treatments where delivery time is limited.
There are several articles summarizing the properties of FFF beams of various linear ac-
celerators, based on Monte Carlo simulations or dosimetric measurements. In all cases,
however, linear accelerators under investigation are FFF prototypes only, created by
mechanically removing a flattening filter from a standard clinical accelerator. A Monte
Carlo evaluation of 6 MV FFF [19] and 18 MV FFF [20] of Varian Clinac 2100 was
reported by MD Anderson Cancer Center. The same group of authors later performed
measurements for 6 MV and 18 MV FFF beams for a Varian Clinac 21EX FFF proto-
type [23]. Similarly, dosimetric properties of 6 MV and 10 MV FFF beams of two Elekta
Precise FFF prototypes can be found [24, 25]. A Monte Carlo simulation of 6 MV and
10 MV FFF beams for Elekta SL25 model is reported by Parsai et al [21].
FFF beams are already utilized clinically in helical tomotherapy [10,43], where a 6 MV
FFF beam is narrowly collimated, typically to a width of 2.5 cm. TrueBeam initiates
the clinical use of FFF bundles for C-arm linear accelerators, enabling the generation
of FFF beams of any field size, being constrained solely by the physical limits of the
accelerator’s collimator.
In this chapter, we report on the accuracy of modeling TrueBeam’s photon beams in
the Eclipse treatment planning system (Varian Medical Systems) using an anisotropic
analytical algorithm (AAA, Varian Medical Systems) [44,45]. There is existing evidence
regarding the performance of the algorithm in homogeneous [46–50] as well as hetero-
geneous media [47–50]. We extend the spectrum of these publications by evaluating an
agreement of the AAA model with measurements for FFF beams. This study is limited
to the verification of the algorithm performance in physics conditions, i.e. in a water
phantom.
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3.2 Materials and methods
3.2.1 Linear accelerator
Photon beams of two nominal energies (6 & 10 MV) of TrueBeam were commissioned.
TrueBeam allows delivery of both nominal energies, with a flattening filter in place or
using so called open port - a carousel position where a thin foil is used instead of a
flattening filter. We further refer to the four photon beams as X6, X6FFF, X10, and
X10FFF. These bundles are available in the following dose rates:
• X6 & X10: 100, 200, 300, 400, 500 & 600 MU/min,
• X6FFF: 400, 600, 800, 1000, 1200 & 1400 MU/min,
• X10FFF: 400, 800, 1200, 1600, 2000 & 2400 MU/min.
TrueBeam handles beam generation and steering as well as dose calibration for each
bundle separately. This approach is different from the practice reported for prototype
machines [19,23], where the absolute calibration was done for a flattened beam, and after
the removal of flattening filter, the machine output was not further adjusted. Beams
were calibrated following the AAPM TG-51 formalism [51]; 100 MU corresponds to 1
Gy at the depth of maximum dose (dmax) for SSD 100 cm and the field size of 10x10
cm2.
3.2.2 Multi-leaf collimator
TrueBeam STx is equipped with a high definition multi leaf collimator (HDMLC, Varian
Medical Systems). This tungsten 120-leaf collimator has 32 leaf pairs of 2.5 mm leaf
projection width in the isocenter, surrounded by 28 leaf pairs of 5.0 mm leaf projection
width. The total length across leaves of HDMLC is 22 cm at the isocentric plane.
3.2.3 Depth dose curves & profiles
All measurements were acquired in a large water phantom (PTW Freiburg, Germany)
at SSD 90 cm. Percentage depth dose curves (PDDs) were acquired for 12 different field
sizes:
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• 1x1 cm2, 2x2 cm2, 3x3 cm2, 4x4 cm2, 6x6 cm2, 8x8 cm2, 10x10 cm2, 12x12 cm2,
15x15 cm2, 20x20 cm2, 30x30 cm2, 40x40 cm2
PDDs for field sizes above 3x3 cm2 were measured with a 0.125 cm3 cylindrical chamber
(PTW31010); for small field sizes a pinpoint chamber (PTW31016) was used to avoid
the partial volume irradiation effect obvious for the larger chamber. Error introduced
by the ion collection inefficiency of both chambers is smaller than 1.3 % (based on
the measurement in the least favorable circumstances - X10FFF, 40x40 cm2, SSD 90
cm, dmax). Radial and transversal profiles of symmetric fields were measured for the
following set of previously specified field sizes and depths of dmax, 5 cm, 10 cm, 20 cm,
and 30 cm. Transverse profiles of asymmetric fields were measured at the depth of 10
cm for the following rectangular fields:
• X x (10 + Y2) and X x (Y1 + 10), where X ∈ {10, 20} cm, Y1 ∈ {-5, 0, 5, 10}
cm, Y2 ∈ {-5, 0, 5, 10} cm
Profiles up to a field size of 15x15 cm2 were measured with a shielded diode detec-
tor (PTW60008), and above this field size, a liquid ionization chamber (microlion,
PTW31018) was used. The shielded diode provides high spatial resolution, but it could
not be used for profiles of larger field sizes as this non-tissue equivalent detector over-
responds to scattered radiation [52]. The difference in profiles between the liquid cham-
ber and the 0.125 cm3 cylindrical chamber was within 1 %, yet profiles measured with
the liquid chamber benefited from sharper penumbra and the elimination of cabling
effects.
3.2.4 Surface dose
A Markus chamber (PTW34045) in a solid water phantom was used to estimate the
surface doses. We have measured the response of the chamber for no build-up (an
entrance window of 0.025 mm of water equivalent material) and for 1 mm solid water
build-up and related these to measurements at the depth of maximum dose.
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3.2.5 Penumbra evaluation
The definition of penumbra width - a difference in position between 80% and 20% relative
dose point of a profile - cannot be applied to FFF beams normalised to the central axis,
as dose inside a field can be as low as 30 % depending on the beam’s energy and field
size (figure 3.1). To overcome this limitation, Po¨nisch et al [53] proposed for FFF beams
normalization to the inflection point of a profile’s penumbra. The same normalization
is used in our study.
Figure 3.1: Measured profiles for all field sizes at 10 cm depth for X6FFF (A) and
X10FFF (B) and for the 30 x 30 cm2 field at all measured depths for X6 and X6FFF
(C) and X10 and X10FFF (D). FFF profiles are represented by black lines; flattened
profiles are indicated by gray lines.
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3.2.6 Out of field dose
To evaluate out-of-field dose, a half-profile of a dose up to 40 cm off the central axis was
measured for X6, X6FFF, X10, X10FFF for the following depths and field sizes:
• field size: 4x4 cm2, 10x10 cm2
• depth: 2 cm, 10 cm, 20 cm
A large water phantom was placed asymmetrically so that the beam’s central axis was
aligned close to a phantom wall, yet ensuring that the entire field remains inside the
water phantom at any depth. The solid water phantom was aligned to the wall of
the water phantom to ensure full scatter conditions. The measurement was performed
with the 0.125 cm3 cylindrical chamber. The previously mentioned normalization to the
inflection point was used.
3.2.7 Changes in the output
To evaluate the delivery efficiency achieved by the removal of the flattening filter, the
dose measured in the reference conditions for 100 MU was related to the charge on the
target. Total scatter factors (Scp) were measured in a large water phantom at SSD 90
cm and the depth of 10 cm for all rectangular field sizes created using the following jaw
positions:
• 1 cm, 2 cm, 3 cm, 4 cm, 6 cm, 8 cm, 10 cm, 12 cm, 15 cm, 20 cm, 30 cm, and 40
cm.
For field sizes down to 3x3 cm2, a 0.125 cm3 cylindrical chamber (PTW31010) was used.
Field sizes below 3x3 cm2 were measured with a shielded (PTW60008) and unshielded
diode (PTW60012) following the recommendation of Schwedas et al [54].
3.2.8 HDMLC transmission and dosimetric leaf gap
HDMLC leaf transmission was determined by a measurement with a Roos chamber
(PTW34001) in a large water phantom at SSD 90 cm for three different depths (5 cm,
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10 cm, and 20 cm). A jaw collimated 8x22 cm2 field, with HDMLC leaves of one carriage
completely blocking the field, was used to acquire transmission profiles across HDMLC
with a liquid ionization chamber (PTW31018). For the determination of the dosimetric
leaf gap (DLG), the sweeping gap method was used [55, 56]. Dose measured by the
Farmer ionization chamber (PTW300013) for a sweeping gap of 1, 10, 20, and 30 mm
was corrected for the HDMLC transmission and the corrected dose was plotted against
the field size. The interpolation of this dataset to zero field size was used as an estimator
of the DLG.
3.2.9 Beam modeling and evaluation of the model
The measured depth dose curves, transverse profiles, diagonal profiles, and output factors
were imported into Eclipse in order to calculate the beam data for the anisotropic
analytical algorithm (AAA 8.9.08, Varian Medical Systems) [44,45]. Profiles and depth
dose curves were modeled by the configured AAA with a calculation grid of 1.5 mm and
exported.
The agreement of the modeled profiles with the measured dataset was evaluated using an
in-house implementation of a one-dimensional gamma [27] approach. The criteria of 1 %
dose difference (DD) and 1 mm distance to agreement (DTA) have been selected. Each
measured - modeled profile pair was individually reviewed and additionally, histograms
were generated from the obtained gamma profiles to quantify the overall agreement
for each bundle and its sub-regions (inside-field, penumbra, out-of-field for profiles and
build-up and fall-off for depth dose curves).
3.3 Results
3.3.1 Depth dose curves
Mean energy of FFF beams is lower than the one of corresponding flattened beams
(see quality indexes in table 3.1). For field sizes between 1x1 cm2 and 30x30 cm2, FFF
beams have the dmax located closer to the surface than the flattened beams (up to
approximately 2 mm for X6FFF and 4 mm for X10FFF). Generally, with increasing
field size, the dmax shifts closer to the surface; this effect is less pronounced for FFF
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Table 3.1: Depth dose curve parameters (2 standard deviations in brackets)
dmax (mm) %dd (0.025 mm) %dd (1 mm) %dd (100 mm) TPR20/10
X6 14.3 ( 0.44) 18.9 ( 0.4) 47.3 (0.4) 66.0 (0.4) 0.667 (0.004)
X6FFF 12.1 (0.17) 24.3 (0.4) 56.1 (0.4) 63.2 (0.2) 0.631 (0.004)
X10 22.3 (0.60) 14.0 (1.0) 32.3 (1.0) 73.5 (0.5) 0.738 (0.004)
X10FFF 21.0 (1.2) 19.1 (1.6) 43.6 (1.0) 69.1 (1.0) 0.692 (0.012)
%dd = percentage depth dose
TPR20/10 = tissue-phantom ratio at the depths of 20 and 10 cm
Table 3.2: Ratios of maximum and minimum dose inside the field (within 80 % of the
field size) for different field sizes measured at 10 cm depth (SSD 90 cm)
Square field size (cm2) 1 2 4 10 20 40
X6 1.41 1.15 1.05 1.05 1.04 1.04
X6FFF 1.39 1.14 1.07 1.13 1.28 1.65
X10 1.45 1.23 1.09 1.04 1.03 1.04
X10FFF 1.45 1.21 1.12 1.25 1.54 2.23
beams however, and therefore the difference in the dmax of flattened and FFF depth
dose curves gradually diminishes and eventually results in deeper located dmax for both
FFF beams for the 40x40 cm2 field size. The surface dose for the field size 10x10 cm2
increases by approximately 10 % (table 3.1).
3.3.2 Profiles
FFF profiles have the maximum dose on the central axis and decrease gradually towards
the field edge. This non-flattened shape becomes more pronounced with increasing field
size and beam energy (figure 3.1, table 3.2). Up to a field size of 3x3 cm2, the in-field
part of a profile is practically the same for X6 & X6FFF, as well as X10 & X10FFF
beams. Smaller profile variations with depth are observed for FFF beams (figure 3.1).
3.3.3 Penumbras
X6FFF penumbra is approximately 0.3 mm sharper than the penumbra of X6 at dmax.
With increasing depth, the difference gradually diminishes and at a depth of 12 cm,
penumbras of X6 and X6FFF are practically identical. Beyond this range, the flattened
beam creates sharper penumbra. For X10FFF, sharper penumbra than for X10 was
measured for all investigated depths, the difference between penumbras reaches up to
0.6 mm at the dmax and slowly decreases with depth. A slight widening of penumbra
with increasing field size was observed for all beams. This widening occurs at a slightly
faster rate for FFF beams. Table 3.3 summarizes penumbra width for selected conditions
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Table 3.3: Measured transverse/radial penumbras (mm) for selected field sizes and
depths
field (mm2) depth (mm) X6 X6FFF X10 X10FFF
10x10 dmax 2.01/2.79 1.77/2.59 2.66/3.19 2.29/2.84
100x100 100 4.09/4.83 3.71/4.93 4.63/5.65 4.25/4.77
150x150 200 6.38/6.30 7.26/8.85 7.20/7.75 6.98/7.60
in the transverse and radial direction. Figure 3.2 summarizes penumbral width for the
highest (X10) and the lowest (X6FFF) energy bundle under investigation as a function
of field size and depth.
Figure 3.2: Penumbra width (in mm) are shown in a transverse direction as functions
of field size and depth for X6FFF (A) and X10 (B). Isolines of penumbra width were
obtained as quadratic least square fit of measured points (presented as crosses). A
root-mean-square deviation of the fit and measurement is 0.13 mm for X6FFF and 0.14
mm for X10.
3.3.4 Out of field dose
Figure 3.3 represents a ratio of (half) dose profiles of a FFF and a flattened beam for
different field sizes and depths. Out-of-field dose deposited by FFF beams is, under
most conditions, lower than for flattened beams. There is a noticeable dose reduction
effect at the edge of a field and at further distances from the edge. At interim region,
the FFF/flattened dose ratio reaches its maximum and under some circumstances, a
FFF beam can deposit more dose than a flattened one in this region. At a distance
of around 20 cm from the central axis, an increment on the dose ratio curve is visible.
With increasing field size and depth, the dose reduction effect of a FFF beam gradually
decreases.
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Figure 3.3: Out-of-field dose ratios for X6FFF/X6 (A, B) and X10FFF/X10 (C, D)
are shown for two selected field sizes.
3.3.5 Changes in the output
Under reference conditions, the dose in the reference point on the central axis produced
by the same charge on the target is 2.26 times higher for X6FFF than for X6; this ratio
is 4.03 for X10FFF. Total scatter factors (Scp) for symmetric fields are plotted in figure
3.4. FFF beams exhibit smaller output variations with field size and the collimator
exchange effect is reduced - the change in Scp for 2x40 cm
2 and 40x2 cm2 rectangular
field is 1.2 % for X6FFF, 1.8 % for X6, 1.5 % for X10FFF and 2.4 % for X10.
3.3.6 HDMLC transmission and dosimetric leaf gap
Both FFF beams have lower transmission than the corresponding flattened beams (table
3.4). Transmission increases with depth for all beams and this effect is most pronounced
for X6FFF. Radial changes in the transmission of FFF beams are smaller (difference in
transmission on the central axis and 10 cm off-axis is 0.16 % for X6FFF, 0.23 % for X6,
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Figure 3.4: Total scatter factors for symmetric fields are shown for X6 and X6FFF
(A), X10 and X10FFF (B).
Table 3.4: Dosimetric leaf gap and transmission of HDMLC (2 standard deviations
in brackets)
DLG (mm) MLC transmission
depth 5 cm depth 10 cm depth 20 cm
X6 0.93 (±0.08) 1.19 % 1.21 % 1.30 %
X10 1.03 (±0.08) 1.38 % 1.39 % 1.41 %
X6FFF 0.91 (±0.07) 0.98 % 1.02 % 1.13 %
X10FFF 1.04 (±0.08) 1.17 % 1.20 % 1.27 %
0.18 % for X10FFF, 0.25 % for X10). A dosimetric leaf gap of approximately 1 mm was
determined for all bundles (table 3.4).
3.3.7 Modeling in Eclipse
In general, a good agreement between the modeled and measured data is observed for
all beams under investigation. Whilst the high dose region of profiles is well modeled
for all bundles, it is obvious that the accuracy of penumbra modeling is limited. The
modeled penumbras are on average 0.7 mm ± 0.4 mm wider than the measured ones.
The impact of less accurate penumbra modeling is accentuated for small field sizes (below
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Table 3.5: Gamma score (GS) and values of different percentiles of γ-histograms for
symmetric and asymmetric profiles and depth dose curves
GS (%) 50 % 75 % 80 % 90 % 95 % 100 %
Profiles (symmetric fields)
X6 96.9 0.24 0.47 0.53 0.73 0.90 1.73
X6FFF 98.1 0.19 0.38 0.44 0.62 0.78 1.77
X10 95.3 0.28 0.53 0.61 0.82 0.99 1.83
X10FFF 94.2 0.18 0.37 0.44 0.71 1.07 2.02
Depth dose curves (symmetric fields)
X6 99.2 0.15 0.29 0.35 0.54 0.70 2.00
X6FFF 99.5 0.15 0.31 0.36 0.47 0.58 1.17
X10 98.3 0.19 0.33 0.36 0.49 0.68 1.87
X10FFF 99.7 0.13 0.25 0.30 0.44 0.66 1.07
Profiles and depth dose curves (asymmetric fields)
X6 96.4 0.35 0.56 0.62 0.78 0.95 1.48
X6FFF 99.2 0.25 0.43 0.48 0.62 0.73 1.43
X10 87.4 0.34 0.68 0.79 1.10 1.37 1.94
X10FFF 91.0 0.22 0.47 0.58 0.95 1.18 1.54
approximately 4x4 cm2) where penumbra creates a proportionally larger part of a profile
(figure 3.5).
The largest discrepancies are observed at the foot - the boundary between the penumbra
and the out-of-field part - of a profile. The discrepancy in this region increases with depth
and is more obvious for X10 and X10FFF bundles. Dose of a measured profile is lower
then the one modeled in this region for all beams. Depth dose curves are well modeled
for all four energies. Good agreement is observed inside the build-up region as well as
beyond the dmax for all field sizes including 1x1 cm
2 (figure 3.6).
Parameters of gamma histograms quantifying the agreement between measured and
modeled curves are summarized in table 3.5. The majority of evaluated points complies
with the selected agreement criteria (1% DD, 1 mm DTA) and the value of gamma is
always smaller than 2. In the out-of-field region of X10 and X10FFF where agreement
was poor, approximately 10 % of the points fail the criteria.
A similar evaluation made for the modeling of asymmetric fields shows a similar level
of agreement, with both FFF beams attaining a slightly better gamma score than the
flattened ones (table 3.5).
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Figure 3.5: Comparison of measured and modeled profiles for X6FFF and X6 and for
X10FFF and X10 at four selected field sizes.
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Figure 3.6: Comparison of measured and modeled depth dose curves are shown for
X6FFF & X6 and for X10 FFF & X10 at four selected field sizes.
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3.4 Discussion
3.4.1 Depth dose curves & profiles
From a qualitative point of view, changes of depth dose curves and profiles induced
by the removal of a flattening filter are consistent with other studies dealing with this
topic [19–21,23–25,57]. As beam hardening does not occur for FFF beams, their mean
energy is lower due to the presence of low energy photons and FFF depth dose curves
have more rapid fall-off. Low energetic photons contribute to the increase of superficial
dose for FFF beams and to the slight shift of dmax closer to the surface. Vassiliev et
al [23] and later Kragl et al [24] explain the shifts of dmax as a result of two competitive
effects: beam hardening for flattened beams (shifts dmax downstream) and larger head
scatter contribution for flattened beams with increasing field size (shifts dmax upstream).
This is supported by our data, where the difference in dmax diminishes with increasing
field size and both FFF beams eventually have dmax for the largest field size located
deeper than flattened beams. The non-flatness of FFF profiles increases with energy as
the probability of photon scattering into lateral directions decreases with the increasing
energy of incident photons. The non-flatness characteristic of X6 and X6FFF (table 2)
is comparable to the one reported by Vassiliev et al for a Clinac 21EX FFF prototype
(measured at SSD 100 cm) [23]. The largest difference is observed for the smallest
field size, TrueBeam’s non-flatness parameter for X6 and X6FFF being approximately
2 % lower than for the 21EX. Smaller variations of FFF profiles with depth may be
attributed to more uniform mean energy in a radial direction [57]. The mean energy of
flattened beams is subject to larger changes due to the variable beam hardening effect
of the non-uniformly thick flattening filter.
3.4.2 Penumbras
The sharper penumbra of FFF beams at shallow depths can be attributed to their lower
mean energy, hence shorter range of secondary electrons. However, less energetic FFF
beams are more prone to scattering, therefore at sufficient depth they will eventually
form a wider penumbra than flattened beams. Increase widening of penumbra of FFF
beams as a function of field size may be due to the profile normalization method. Kragl
et al [24] report non significant differences in penumbra for flattened and FFF beams of
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prototype Elekta linacs. Po¨nish [53] reports 0.5 mm penumbra reduction for X6FFF of
Clinac 2100 prototype for a field 10x10 cm2 and 10 cm depth.
3.4.3 Out-of-field dose
Out-of-field dose evaluation for the Clinac 2100 FFF prototype, based on Monte Carlo
simulation, was recently published [58]. Our measurements for TrueBeam concur quali-
tatively with the simulation. The ratio of dose profiles outside a field is a result of two
competing effects: decrease of collimator scatter and head leakage, and increase of phan-
tom scatter resulting from lower mean energy of FFF beams [58]. Increased phantom
scatter constrains the dose reduction potential of FFF beams.
The comparison of FFF and flattened profiles partially depends on the method used for
their normalization, especially for larger field sizes and higher nominal energy where a
difference in shape between FFF and flattened profile is more accentuated. In our opin-
ion, the normalization to penumbra represents an extreme option that maximizes the
difference in primary dose deposited in a phantom for a FFF and flattened beam. The
additional contribution of primary dose proportionally creates additional scatter; hence,
the comparison of profiles normalized to penumbra can be understood as the worst case
scenario of dose reduction for FFF beams.
In clinical situations, dose outside of the target will be influenced by many parameters
such as size, location, and shape of the target as well as the degree of modulation and
delivery technique used (IMRT or VMAT) and their interplay with beam characteristics
(energy and shape of a profile). As is obvious from the measured data (figure 3.3), the
best possible dose reduction outside a field will be in general achieved for small field
sizes and higher energy FFF beams.
3.4.4 Changes in the output
The observed increase in the dose delivery efficiency resulting from the flattening filter
removal is consistent with data published in Vassiliev et al [23] (2.3 for X6FFF and
5.5 for X18FFF). Less dependence of the output on field size and reduced collimator
exchange effect for FFF beams related to the reduction of head scatter is comparable
with other reports [23,24,53].
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3.4.5 HDMLC transmission and dosimetric leaf gap
Lower transmission and its smaller off-axis variation are related to the lower and more
uniform mean energy of FFF beams [57]. Larger variation of transmission with depth
for low energetic beams may be attributed to more pronounced MLC beam hardening
effect.
3.4.6 Modeling in Eclipse
Eclipse modeling of the four beams is generally accurate. The selected criteria - 1 %
DD and 1 mm DTA - seem to be reasonable and is achieved in the majority of the
investigated points for symmetric as well as asymmetric fields. The worst gamma score
result (87 %) was observed for the group of asymmetric profiles of the X10 bundle. The
value of gamma is always below 2, meaning if the criteria of 2 mm DTA and 2 % DD
were selected, these values would always be attained.
Omitting the outliers in the gamma histograms, there is lower occurrence of higher
gamma values for both FFF bundles (table 5) and one could therefore anticipate that
the modeling of FFF bundles is easier. AAA uses only a single source model for FFF
beams. The second (virtual) source, which model dose contribution from the extra-focal
radiation in flattened beams, is left out for FFF beams as the majority of extra-focal
photons originate from a missing flattening filter. This approach appears to ensure a
good performance also for asymmetric fields where the model agreement is slightly bet-
ter for FFF beams as well (table 5).
The agreement with the measurement is not only influenced by the quality of the beam
model, but also by imperfections in the measured dataset. To reduce these imperfec-
tions, all profiles were aligned and normalized prior to the evaluation. Influences of the
discrete character and noise in the measured profiles are partially suppressed by the used
algorithm for 1D gamma analysis [27]. There was not any measure taken to symmetrize
beams, which influenced the agreement evaluation for the X10FFF bundle where a slight
(clinically acceptable) asymmetry of the beam is the cause of several points with higher
gamma values in the high dose region of a profile. X10FFF is the only bundle that
exhibits higher gamma values in this region.
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3.5 Conclusion
Basic dosimetric properties were summarized for four photon beams of the first clinically
used TrueBeam STx linear accelerator. All bundles were successfully modeled by the
analytical anisotropic algorithm with an acceptable level of agreement with measured
data.
Chapter 4
Ion-recombination correction for
different ionization chambers in
high dose rate flattening filter
free photon beams1
4.1 Introduction
Recently, there has been an increased interest in flattening-filter-free (FFF) linear ac-
celerators [23–25, 42]. Removal of the filter results in available dose rates up to 14 and
24 Gy min−1 for nominal energies of 6 and 10 MV (in depth of maximum dose (dmax),
a source-surface distance (SSD) of 100 cm and a field size of 10 x 10 cm2), respectively.
To guarantee accurate relative and reference dosimetry for such FFF beams, we inves-
tigated the charge collection efficiency of multiple air-vented and one liquid ionization
chamber for dose rates up to 31.9 Gy min−1.
The two main processes leading to ion recombination are “initial recombination” and
“general recombination”. Initial recombination is caused by the recombination of two
particles originating from the same particle track. It has been previously shown by sev-
eral authors that within air-vented ionization chambers this contribution is minimal and
1This chapter has been published as a manuscript [29]: S. Lang, J. Hrbacek, A. Leong, and S. Klo¨ck,
“Ion-recombination correction for different ionization chambers in high dose rate flattening-filter-free
photon beams,” Physics in Medicine and Biology, vol. 57, no. 9, p. 2819, 2012.
48
Chapter 4: Ion-recombination correction 49
independent of dose rate [59,60]. General recombination occurs when particles originat-
ing from different particle tracks recombine. Boag [61] developed a theoretical method
to account for the general recombination in both pulsed and continuous beams. He
proposed the two-voltage method [62] to determine the correction for incomplete col-
lection of ions at sufficiently high applied voltages. Since then numerous investigations
regarding the ion-collection efficiency of different chambers used for reference dosimetry
under a range of conditions have been published [59,60,63–65]. Recently, Bruggmoser et
al [65] determined saturation coefficients for a selection of plane parallel and cylindrical
chambers in pulsed photon and electron beams up to 42 mGy pulse−1.
For liquid ionization chambers, the two-voltage method cannot be applied because the
effect of initial recombination cannot be neglected due to the high ionization density
in the particle track and the short mean free path of ions in liquid [66–68]. Moreover,
initial recombination is affected by the applied voltage and thus leads to a dependence of
the general recombination efficiency upon the applied voltage. Pardo-Montero et al [69]
developed and verified a three-voltage method as well as a modified two-voltage method
to determine charge-collection efficiency in parallel plate liquid ionization chambers.
In this chapter, we contribute to these investigations a detailed analysis of recombination
effects in several air-vented ionization chambers as well as one liquid ionization chamber
using pulsed high dose rate photon beams without a flattening filter. This chapter is
the first systematic study of the performance of ionization chambers with an FFF ac-
celerator commissioned for clinical use. Earlier investigations have been limited to high
dose per pulse (DPP) electron beams [65]. While the clinical use of the FFF is rapidly
increasing [70] detailed studies regarding the behaviour of commonly used detectors in
conjunction with these beams are lacking.
The beam pulse pattern of both FFF and flattened beams were analysed to show the in-
fluence of dose rate, DPP and pulse repetition frequency (PRF) on collection efficiency.
Detectors used for reference as well as relative dosimetry were investigated to ensure
that the depth-dose curves and profiles were not distorted due to insufficient charge
collection within high dose rate regions.
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4.2 Material and methods
4.2.1 Linear accelerator and beam characteristics
Experimental data were collected using a Varian TrueBeam linear accelerator (Varian
Medical Systems, Paulo Alto) at nominal energies of 6 and 10 MV with and without a
flattening filter in the beam path (X6, X10 and X6FFF, X10FFF, respectively). The
characteristics of the four beams have been previously described in detail by Hrbacek
et al [42]. For X6 and X10 beams, dose rates between 1 and 6 Gy min−1 (dmax, SSD
= 100 cm, 10 x 10 cm2) are clinically available. By comparison, X6FFF allows dose
rates between 4 and 14 Gy min−1, while X10FFF allows dose rates between 4 and 24
Gy min−1 (dmax, SSD = 100 cm, 10 x 10 cm2).
Table 4.1 summarizes the parameters regarding the beam pulse pattern of the four
energies at respective minimum and maximum dose rates. The DPP and PRF were
measured with the Delta4 phantom (ScandiDos, Uppsala). At the maximum dose rate,
the PRF was equal for all beams. The increased dose rate of FFF beams is due to
the increased DPP relative to flattened beams. Reduction of the dose rate is achieved
within the TrueBeam system by changing the PRF, whilst maintaining the same DPP.
For X6 and X10, pulses are generated at regular intervals (every 2.8 ms at the maximum
dose rate). For X6FFF and X10FFF, however, every fourth to fifth pulse is omitted.
Therefore, for X6 and X10 DR, the DPP and PRF can be related but not for the FFF
beams.
4.2.2 Detectors under investigation
The general ion-collection efficiency at different DPP and PRF was determined for the
following six ionization chambers in total:
• PTW 34 001 Roos chamber,
• PTW 34 045 Advanced Markus Chamber,
• PTW 31 010 Semiflex chamber,
• PTW 31 016 PinPoint chamber,
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Table 4.1: Basic characteristics of the beam pulse pattern for the four beams available
on TrueBeam inear accelerator. Dose rate ranges (DRR)(measured at the depth of
maximum dose (dmax), SSD = 100 cm, field size of 10 x 10 cm
2 and measured for the
dmax, SSD = 90 cm, field size 40 x 40 cm
2), time between two pulses and DPP (dmax,
40 x 40 cm2, SSD = 90 cm) were measured using Delta4 phantom (ScandiDos, Sweden).
For X6 and X10 beams, pulses are generated at regular intervals (every 2.78 ms at the
maximum dose rate); however, for X6FFF and X10FFF every fourth to fifth pulse is
omitted.
Dose rate range (10x10) Dose rate range (40x40) Time between pulses DPP in dmax
Beam Gy min−1 Gy min−1 ms mGy
X10FFF 4.0-24.0 5.3-31.9 16.7-2.8 1.7
X6FFF 4.0-14.0 5.6-21.6 9.7-2.8 1.1
X6 1.0-6.0 1.4-8.6 16.7-2.8 0.4
X10 1.0-6.0 1.4-8.4 16.7-2.8 0.4
Table 4.2: Basic specifications of the chambers (PTW, Freiburg) investigated: four
different thimble (t) chambers and two plane-parallel (pp) chambers. Chambers differed
in terms of active volume, applied voltage and geometry. The microLion chamber is
filled with liquid isooctane. All other chambers are vented and respectively filled with
air.
DRR (10x10) DRR (40x40) Time between pulses DPP in dmax
Beam Gy min−1 Gy min−1 ms mGy
31 010 Semiflex t 0.125 +400 0.100
31 016 Pinpoint t 0.016 +400 0.060
34 001 Roos pp 0.350 +200 0.125
34 045 AdvMarkus pp 0.020 +300 0.022
30 013 Farmer t 0.600 +400 0.140
31 018 microLion t/liquid 0.002 +800 5.300
• PTW 30 013 Farmer chamber,
• PTW 31 018 microLion chamber, liquid ionization chamber.
Details on the chambers, provided in the manuals of the vendor (PTW, Freiburg), are
summarized in table 4.2.
4.2.3 Ion-collection efficiency for gas-filled chambers
According to Boag [61], the ion-collection efficiency of an air-vented ionization chamber
in pulsed beams can be expressed as follows:
f = u−1ln(1 + u), (4.1)
where
u = µρ
d2
V
. (4.2)
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µ is a constant involving the ion-recombination coefficient and mobilities, ρ is the pulse
charge density, d is the equivalent electrode spacing and V is the polarizing voltage. For
small charge densities, this formula can be expanded up to the first-order term, which
leads to a description of the saturation correction:
kS =
1
f
= 1 +
µ
2
ρ
d2
V
. (4.3)
For chambers that follow this relation, the saturation coefficient kS can be determined
using Boag’s two-voltage method [62]:
kS =
V1
V2
− 1
V1
V2
− Q1Q2
. (4.4)
V1 is the operating voltage and V2 is an arbitrary voltage (smaller than the operating
voltage), and Q1 and Q2 are the collected charges at these voltages. We determined the
correction factors for all air-vented filled ionization chambers according to this formula.
The operating voltages V2 for the chambers can be found in table 4.2. V2 was chosen to
be half of V1, as recommended by Almond [51].
All measurements were performed for a geometry, which maximizes the dose rate, i.e.
shortest SSD within commissioning relevant limits (90 cm), largest field size 40 x 40
cm2), and at the depth of maximum dose. The dose corresponding to 100 MU was
• 1.40 Gy at depth of 1.21cm for X6FFF,
• 1.33 Gy at depth of 2.10 cm for X10FFF,
• 1.46 Gy at depth of 1.43 cm for X6,
• 1.40 Gy at depth of 2.23 cm for X10.
This resulted in a DPP of 1.1 mGy for X6FFF, 1.7 mGy for X10FFF, 0.4 mGy for X6
and 0.4 mGy for X10. The dependence of ion-collection efficiency upon PRF, DPP and
beam energy was studied
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4.2.4 Ion-collection efficiency for liquid ionization chambers
In liquid ionization chambers, the influence of initial recombination cannot be neglected.
The charge released within the chamber is dependent upon the applied voltage. If the
DPP is low and the time between pulses is longer than the ion-collection time of the
chamber, the collected charge Q will relate linearly to the applied voltage V [69]:
Q = Q0(1 + cV ). (4.5)
We determined the coefficients c and Q0 at the PRF less than 100 Hz and a DPP of 0.03
mGy (SSD = 120 cm, depth = 25 cm, X6 and X10). According to the modified two-
voltage method of Pardo-Montero et al [69], which is valid so long as the ion-collection
time is small relative to the time between two consecutive pulses, the ion-collection
efficiency can be determined as follows:
f =
(1 + cV2)
2V1Q1 − (1 + cV1)(1 + cV2)V2Q1
(1 + cV2)2V1Q1 − (1 + cV1)2V2Q2 . (4.6)
According to this method, we determined the collection efficiency of the liquid ionization
chamber for all four beams at the lowest available PRF (time between two pulses >ion-
collection time of 5.3 ms). For a higher PRF, the relative collection efficiency compared
to the Markus chamber was determined. The ratio of reading between the liquid-filled
chamber and the Markus chamber was compared for different doses per pulse. DPP was
changed by varying the measurement depth (2-30 cm) as well as the SSD (SSD = 90 cm
and SSD = 120 cm). The collection efficiency of the Markus chamber was above 0.994
(shown in the first part of the results) and therefore neglected for the relative comparison
to the liquid ionization chamber. For the lowest DPP (SSD = 120 cm, depth = 30 cm),
the ratio was set to 1, as it is known that the collection efficiency is high (above 0.995)
for a DPP below 0.3 mGy [71].
4.2.5 Propagation of uncertainty
Q1 and Q2 were measured multiple times and mean values and standard deviations of
the mean uQ1 and uQ2 were calculated. Using uncertainty propagation, the standard
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deviation for the ion-collection efficiency uf was calculated according to
f =
√(
δf
δQ1
uQ1
)2
+
(
δf
δQ2
uQ2
)2
. (4.7)
4.3 Results
4.3.1 Ion-collection efficiency for air-vented chambers
Table 4.3 summarizes the ion-collection efficiency factors of all investigated air-vented
chambers for all four beams. The collection efficiency was above 0.985 (2uf = 0.002) in
all cases. The Markus chamber demonstrated the largest collection efficiency 0.994 (2uf
= 0.002) for X10FFF; 0.997 (2uf = 0.001) for X6 and X10). The collection efficiency was
independent of the PRF (figure 4.1), implying that for a given beam with a specific DPP
the collection efficiency does not change with the dose rate. Figure 4.1 illustrates the
dependence of the Farmer chamber upon the PRF. The Farmer chamber demonstrated
the longest collection time of all the air-vented chambers (table 4.1), whereas, all other
chambers showed a deduced dependency on the PRF.
Figure 4.1: Dependence of collection efficiency on the PRF when using the Farmer
chamber (PTW, Freiburg). According to table 4.2, the Farmer chamber has the longest
ion-collection time (air-vented chambers), so all other chambers depend less on the PRF.
By altering the time between pulses, the dose rate was varied. For the X10FFF beam,
dose rates of 2400 and 400 MU min−1 correspond to a time between pulses dt = 2.78
ms and dt = 16.67 ms, respectively.
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Figure 4.2: Ion-collection efficiency decreases linearly with increasing DPP for the
Farmer chamber, SemiFlex chamber and Roos chamber (all PTW, Freiburg). (X10FFF:
DPP = 1.73 mGy, X6FFF: 1.08 mGy, X6: 0.4 mGy and X10: 0.39 mGy).
Figure 4.3: Relative ion-collection efficiency of the microLion chamber (PTW,
Freiburg) for the four beams at the minimum and maximum PRF decreases with in-
creasing DPP. The results obtained using the modified two-voltage method (absolute
collection efficiencies) agree well with the relative measurements (compared with the
advanced Markus chamber, PTW). The collection efficiency was dependent upon the
DPP and the time between two pulses dt. The collection time of the microLion chamber
was 5.3 ms.
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Table 4.3: Ion-collection efficiencies of the five air-vented ionization chambers (PTW,
Freiburg) at the depth of maximum dose, field size 40 x 40 cm2 and SSD = 90 cm. The
two standard deviations are given in parentheses.
X6 X10 X6FFF X10FFF
Chamber (DPP = 0.4 mGy) (DPP = 0.4 mGy) (DPP = 1.1 mGy) (DPP = 1.7 mGy)
Semiflex 0.995 (0.003) 0.995 (0.001) 0.991 (0.001) 0.988 (0.001)
Pinpoint 0.991 (0.001) 0.999 (0.001) 0.990 (0.002) 0.990 (0.003)
Farmer 0.997 (0.001) 0.997 (0.002) 0.992 (0.001) 0.989 (0.002)
AdvMarkus 0.999 (0.001) 0.999 (0.001) 0.998 (0.001) 0.994 (0.002)
Roos 0.997 (0.001) 0.996 (0.001) 0.992 (0.001) 0.986 (0.002)
The collection efficiency corrections for 6 and 10 MV beams did not significantly differ.
Figure 4.2 illustrates the relationship between ion-collection efficiency and DPP; the
collection of charge became less efficient with increasing DPP (table 4.1 shows the DPP
for all four beams). Extrapolating the linear fit of the data to zero shows the initial
recombination of all chambers below 0.2 % (2uf = 0.1 %), except for the PinPoint
chamber that generated an initial recombination of 0.87 % (2uf = 0.2 %).
4.3.2 Ion-collection efficiency for liquid-filled chambers
The coefficient c that describes the relationship between produced charge and applied
voltage equation 4.5 was determined to be 0.001123 V−1 (u = 3.30 x 10−55 V−1). Figure
4.3 shows the relationship between DPP and collection efficiency for both methods. The
collection efficiency was seen to decrease with increasing DPP and PRF. Both methods
show comparable results. The collection efficiency for flattened beams was above 0.99.
With increasing DPP, the collection efficiency decreases to approximately 0.96 for the
X10FFF at a low PRF and 0.94 at a high PRF (both DPP = 1.7 mGy).
4.4 Discussion
4.4.1 Ion-collection efficiency for air-vented chambers
Our results confirm that air-vented chambers can be used for relative dosimetry of
FFF beams without correction for collection efficiency. When applied for the reference
dosimetry, a collection efficiency of 0.991 (for X10FFF) and 0.998 (for X6) was found
for the Farmer chamber at the reference geometry (SSD = 100 cm, depth = 10 cm, field
size 10 x 10 cm2).
For the PinPoint chamber, a low ion-collection coefficient for all four beams was found
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as well as a very high initial-recombination factor. Agostinelli et al [72] reported for
the PinPoint chamber (PTW 31014) that the saturation curve was not linear above 150
V. Therefore, the two-voltage method leads to an underestimation of the collection effi-
ciency by approximately 0.5 % (for an applied voltage of 400 V). The design of the two
PinPoint chambers PTW 31 014 and PTW 31 016 is very similar. It is therefore likely
that the PTW 31 016 chamber operated at 400 V was also within the nonlinear region
and the collection efficiency using the two-voltage method was underestimated.
Results obtained for the collection efficiency of the Roos and Farmer chamber are in a
good agreement with those published by Bruggmoser et al [65]. Their calculated collec-
tion efficiency of 0.985 % in pulsed electron beams (for a DPP of 1.7 mGy) corresponds
with our measurement of the X10FFF beam. The collection efficiency for doses per pulse
of 1.1, 0.41 and 0.39 mGy were determined to be 0.990, 0.996 and 0.9965, respectively.
Similarly, we found 0.992 % (X6FFF, DPP = 1.1 mGy), 0.996 % (X6, DPP = 0.4 mGy)
and 0.9965 % (X10, DPP = 0.4 mGy)). Using the Farmer chamber, Bruggmoser et
al [65] published slightly lower collection efficiencies (0.981 at DPP = 1.7 mGy, 0.989 at
DPP = 1.1 mGy and 0.9955 at 0.41 mGy). However, a different polarizing voltage was
applied (300 V rather than 400 V).
4.4.2 Ion-collection efficiency for liquid-filled chambers
The microLion chamber had an ion-collection efficiency of 0.94 when exposed to the
X10FFF beam at the maximum dose rate. An ion-collection efficiency correction should
therefore be applied for both reference and relative dosimetry. Lowering of the dose
rate increased the ion-collection efficiency because the time between pulses became long
enough for the pulses to be fully collected. Measuring the depth-dose curves of a 10 x
10 cm2 field (X10FFF, DR 24 Gy min−1), the collection efficiency varied from 0.941 at
the depth of maximum dose to 0.977 at 30 cm depth. Normalizing the beam to the dose
maximum, as is a common practice, leads to an overestimation of dose in the tail region
of the depth-dose curve. This discrepancy increased with depth.
Most liquid-filled ionization chambers described in the literature have a larger active
volume [73, 74] or use a different liquid [75] than the microLion chamber. A similar
chamber design was evaluated by [71]. For a 6 MV beam with dose rate of 1 Gy
min−1 and DPP of 0.36 mGy, a collection efficiency of 0.995 was determined. This is in
agreement with our result (0.996 (u = 0.005)). Wickman et al [76] reported a collection
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efficiency of 0.9945 for pulsed radiation at a PRF of 100 Hz, which reduced to 0.992
when the PRF was increased to 200 Hz. In our study, a similar reduction was observed
when the PRF was increased to 330 Hz.
4.5 Conclusion
Five commonly used air-vented ionization chambers were investigated to determine their
collection efficiency in the high dose rate and high DPP FFF photon beams. For all
chambers, the collection efficiency was above 0.986 and can therefore be used reliably
for relative dosimetry. The Markus chamber demonstrated the largest ion-collection
efficiency (0.994 at DPP = 1.7 mGy, X10FFF beam). The order of correction for
reference dosimetry is given within the manuscript.
Additionally, the performance of the iso-octane-filled microLion chamber was tested.
The ion-collection efficiency for flattened beams was above 0.99 for both investigated
beams at all dose rates. However, we observed a relatively low collection efficiency of
0.960 for the X10FFF beam at a dose rate of 5.32 Gy min−1. Increasing the dose rate
to 31.9 Gy min−1 further decreased the collection efficiency to 0.940. It is therefore not
advisable to use this chamber for FFF depth-dose curve measurements.
Chapter 5
Effect of high dose per pulse
flattening filter-free beams on
cancer cell survival 1
5.1 Introduction
The question to what extent treatment delivery time or dose rate impact tumour cell
survival has a long history in radiation therapy. While there is increasing evidence in
the recent literature that extended delivery time might impact cancer cell survival, there
is a paucity of studies investigating the potential effect of modified dose rate on cancer
cells [77–81].
New technologies have revolutionized radiation oncology within the last decade. Ap-
plying the treatment dose to the patients using innovative techniques such as intensity-
modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT),
dose conformity to the tumour is increased while sparing of healthy tissue is optimized.
This advantage is achieved through radiation fields which are highly spatially and tem-
porally regulated by modifying dose rate as well as beam shape. Furthermore, technical
achievements within recent years (VMAT, flattening filter-free beam = FFF) allow us
to deliver significantly faster radiation treatment to the patient compared with standard
1This chapter has been published as a manuscript [30]: I. Lohse, S. Lang, J. Hrbacek, S. Scheidegger,
S. Bodis, N. S. Macedo, J. Feng, U. M. Lu¨tolf, and K. Zaugg, “Effect of high dose per pulse flattening
filter-free beams on cancer cell survival,” Radiotherapy and Oncology, vol. 101, no. 1, pp. 226-232,
2011.
59
Chapter 5: Effects on cancer cell survival 60
radiation techniques. Based on recent literature, there is increasing evidence that mod-
ulation of delivery time and/or dose rate can effect tumour cell survival. The clinical
significance of this observation, as well as the underlying molecular mechanisms, remains
unclear.
Data from Shibamoto et al. suggested that beam interruptions greater than 8min, and
treatment delivery times exceeding 20 min, require dose escalation to compensate for
greater sublethal damage repair [82]. Using a theoretical approach and in vitro studies,
Keall et al. demonstrated that extended treatment time is a dominant factor which
influences cell survival [83]. Furthermore, Moiseenko et al. showed an increased clono-
genic survival for a 5 min IMRT head-and-neck treatment compared to a 1 min acute
radiation delivery [84]; data which are supported by the findings of Mu et al. [85]. Us-
ing dosimetric studies, Murphy et al. theoretically demonstrated that different tumour
locations within an IMRT plan experience highly differentiated dose-rate histories [86].
Bewes et al. found a significant trend to increased survival as the average dose rate
was decreased, while keeping the total dose constant. In addition, their in vitro studies
showed that extended delivery times can substantially increase cell survival [87]. These
preliminary data suggest that modulating delivery time, and to a lesser extent, dose rate
when treating cancer patients with ionizing radiation might have a profound impact on
tumour cell survival. Due to recent technical improvements in radiation therapy, (e.g.
IMRT, VMAT, flattening filter-free (FFF) technology etc.), there is an urgent need to
further elucidate the biological response of modulating dose rate or delivery time on
tumour cells and to better understand the molecular mechanism underlying the spa-
tiotemporal modulation of ionizing radiation, and specifically, its clinical significance.
On March 16 2009, the TrueBeam STx linear accelerator (Varian Medical Systems,
Palo Alto, CA, USA) was released for clinical use at the University Hospital of Zurich,
Switzerland. This new generation of linear accelerators enables us to apply a wide spec-
trum of clinically relevant treatment regimens, including those with an extremely high
dose rate (from stereotactic single high dose to classic fractionated treatment regimens).
Using the so-called FFF technique allows the radiation dose to be delivered up to four
times faster than with current modalities. While this is of clinical advantage (shorter
treatment time significantly correlates with higher precision of radiation fields due to
reduction of organ movement or patient’s displacement), no radiobiological studies have
established whether such a high dose-rate translates into a differential stress response
and cell survival pattern in tumour versus normal cells.
Chapter 5: Effects on cancer cell survival 61
As previously published by our group and others, FFF beams show a lower mean energy,
an increased dose per pulse (instantaneous dose rate), a lower pulse repetition frequency,
as well as a different beam profile compared to a beam of the same average dose with
the flattening-filter in place [24, 42]. Undertaking in vitro experiments at the same lin-
ear accelerator using two beams with the same average dose rate but with and without
flattening filter allows us, for the first time, the possibility to maintain treatment condi-
tions as identical as possible. The goal of this study is to investigate if this difference in
beam characteristic, especially the increase in dose per pulse, translates into a different
radiobiological response in tumour cells. In addition, we examine the effect of changing
the dose rate from 400 to 2400 cGy/min on cancer cell survival while keeping the dose
per pulse constant.
5.2 Material and methods
5.2.1 Cell culture
The human glioblastoma cell lines T98G (expressing mutated p53), and U87-MG (ex-
pressing functional p53) were purchased from the American Type Culture Collection
(ATCC). The cells were maintained in monolayer culture in Dulbecco’s Modified Ea-
gle Medium (DMEM) supplemented with 10% FBS, 1% L-Glutamine and 1% Peni-
cillin/Streptomycin. All cells were grown in a humidified atmosphere of 5% CO2 at 37
°C.
5.2.2 Irradiation
Using the TrueBeam STx linear accelerator (Varian Medical Systems, Palo Alto, CA,
USA) a pulsed photon beam of the nominal energy of 10 MV was generated with flatten-
ing filter (X10) and compared to the beam of the same nominal energy without flattening
filter (X10FFF). Each beam can be produced at different dose rates (DR), which are
achieved by modifying the pulse repetition frequency (PRF). The change of DR does
not influence the dose per pulse (DPP). Table 5.1 summarizes the quality index (QI),
which is an indicator for mean energy, DPP, and PRF for beams and DR used in our
experiments.
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Table 5.1: Beam characteristics
energy QI DPP DR PRF time to deliver 5 Gy
(cGy/pulse) (cGy/min) (Hz) (s)
X10 FFF 0.691 0.13 2400 360 12.5
X10 FFF 0.691 0.13 400 60 75
X10 0.735 0.028 600 360 50
X10 0.735 0.028 400 240 75
X10 0.735 0.028 20 12 1500
Irradiation of samples was performed at source-to-surface distance of 100 cm, field size
10x10 cm2 and at the depth of maximum dose. The samples were placed on 5 cm of
water equivalent RW3 plates (PTW). The build-up for every beam was provided by RW3
plates of appropriate thickness placed on top of the samples. In the reference conditions,
100 monitor units (MU) corresponded to 100 cGy, hence dose per pulse expressed in the
units of MU/pulse or cGy/pulse was the same.
In our study we investigated the effect of four different combinations of DPP and PRF
on cancer cell survival: X10 20 cGy/min, X10 400 cGy/min, X10FFF 400 cGy/min, and
X10FFF 2400 cGy/min. As the control experiment, X10FFF was compared to X10 in
the conditions of identical DPP, PRF, and dose. To achieve the same DPP for X10 and
X10FFF beam, additional layer of attenuation material ensuring 4-fold DPP reduction
was introduced in the experimental setup for X10FFF beam (in total 30.5 cm of RW3
plates). To irradiate with the same PRF, a DR of 400 MU/min and 1600 MU/min was
used for X10 and X10FFF beam, respectively. To deliver the same dose the number of
MUs was increased by a factor of four.
To deliver a homogenous dose to all samples, we used Petri dishes of 3cm diameter. Three
samples were irradiated at the same time when treating with the flattened beams and
only one sample when treated with the flattening filter free beams due to the differences
in dose profiles. An analysis of the dose beam profiles of corresponding beams shows
that the dose rate within the samples did not vary more than ±2 %.
5.2.3 Dose verification
For both energies, verification of the applied dose was performed using gafchromic film
(EBT2, ISP), placed above and under the Petri dishes, performed in duplicates on four
different days. In a third separate experiment, film was placed within the dishes on top
of the medium. Films were scanned using Epson 10,000XL Scanner and an individual
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five-step calibration in solid water was done to convert density to dose.
Measurements of absolute dose in the equivalent depths of water (2.2 cm for X10, 2.1
and 30.5 cm for X10FFF) were performed using a pinpoint chamber (results not shown).
The output of the linear accelerator was checked prior to each experiment using the
LinaCheck device (PTW, Freiburg).
5.2.4 Clonogenic assay
Exponentially growing cells were plated into 3 cm Petri dishes. Cells were exposed to
5 or 10 Gy of irradiation. Following irradiation, cells were incubated for 10-14 days at
37 °C in a humidified atmosphere of 5% CO2 for colony formation. Colonies were fixed
with methanol, stained with 1% crystal violet and counted. Colony plating efficiency
was calculated as previously described [88].
5.2.5 Statistical analysis
All data are presented as means ± standard deviation (SD). The data was analysed
using the statistical programme SPSS version 16.0 (SPSS Inc., Chicago, IL). Differences
among the groups were compared by one-way analysis in combination with post hoc
Scheffe test. Two-tailed values of p <0.05 were considered significant.
5.2.6 Bio-mathematical model
For fitting the experimental data, the Γ-LQ-model [89] was used. The kinetic model
consists of a part describing killing of tumour cells (tumour cell number N = N(t))
and a part to include cellular repair mechanisms by a dose equivalent Γ = Γ(t). The
equations describing the model are the following:
dΓ
dt
= R− γΓ2
dN
dt
= (α− 2βΓ)RN (5.1)
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Here, R = R(t) is the dose rate, which can be an arbitrary function of time. In the fol-
lowing, two different dose rate functions are used: a constant dose rate (20, 400 and 2400
cGy/min) and a pulsed dose rate function according to the beam characteristics in table
5.1. The coefficient γ describes the effectiveness of repair, with units of Gy−1 min−1. For
including cellular repair, a second order kinetic is assumed. In figure 5.1 the time depen-
dent course of Γ(t) is illustrated for pulsed dose application: Γ(t) is accumulated during
a pulse and is faded away for γ 6= 0 Gy−1 min−1 between two pulses due to the repair
of sublethal entities. The value γ = 0 Gy−1 min−1 leads to the classical LQ-formalism.
It has been demonstrated previously [89], that the use of a dose rate dependent value of
γ is in good agreement to the LPL-model of Curtis [90] when using second order repair
kinetics. The parameters α and β are coefficients for radio-sensitivity.
Equation 5.1 have been implemented in a computer programme and were solved numer-
ically by the Runge-Kutta integration.
Figure 5.1: Time dependent course of the dose equivalent Γ(t) for pulsed dose appli-
cation, according beam characteristics. Upper curve: R = 2400 cGy/min, PRF = 360
Hz. Lower curve: R = 400 cGy/min, PRF = 60 Hz.
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5.3 Results
5.3.1 Increased treatment time increases tumour cell survival
For our study we used flattened as well as FFF beams generated by the TrueBeam STx
linear accelerator. Since these two beams differ in their beam profile, we first performed
experiments to verify the accuracy of dose application to our in vitro model system
as well as the standard deviations within treatments. Two established glioblastoma
cell lines, T98G and U87-MG, were irradiated with either 5 or 10 Gy at 10 MV using
different dose rates: 20, 400, or 2400 cGy/min. Due to technical limitations of the
TrueBeam STx linear accelerator, irradiation using dose rates of 20 and 400 cGy/ min
was performed using the flattened X10 beam, while the dose rate of 2400 cGy/min was
applied using the flattening filter-free X10FFF beam. The first two dose rates (20 and
400 cGy/min) differ in PRF with constant DPP, while 400 and 2400 cGy/min differ in
DPP as well as PRF. For all three treatments, delivery time and mean dose are altered
(figure 5.2 A). Gafchromic films were placed underneath the samples to verify the applied
dose. The X10 FFF beam delivered 4.92 Gy (±0.11 Gy)/9.79 Gy (±0.16 Gy) and X10
beam 4.92 Gy (±0.12 Gy)/9.82 Gy (±0.17 Gy). Gafchromic films inside the PetriDishes
measured a dose of 4.82 Gy (X10FFF) and 4.86 Gy (X10). Day to day variation of the
output of the linear accelerator was within 1% for both energies. The analysis of the
clonogenic assays revealed that cells irradiated with a dose of 5 Gy showed a reduction
in clonogenic survival in a dose rate-dependent fashion, but the reduction of cell survival
was only statistically significant in cells irradiated with 2400 cGy/min if compared to
cells irradiated with 400 cGy/min (figure 5.2 B). In contrast, clonogenic survival was
markedly reduced upon irradiation with a total dose of 10 Gy and increasing dose rates
(figure 5.2 C) in both cell lines (*p ≤ 0.05; **p ≤ 0.001).
These data show that increasing dose rates and decreasing delivery time lead to a reduc-
tion of clonogenic survival in T98G and U87-MG and that this effect is more pronounced
when treating the cells with the higher dose of 10 Gy compared to 5 Gy and using the
FFF technique. This observation might be due to an overload of the DNA damage
repair machinery due to the higher dose and number of pulses per minute or to other
so far unknown molecular mechanisms triggered by high radiation doses. During this
Chapter 5: Effects on cancer cell survival 66
Figure 5.2: IR efficacy is increased with increasing dose rates. (A) Beam character-
istics of the treatment as indicated. (B, C) T98G (empty bars) and U87-MG (filled
bars) cells were irradiated with (B) 5 Gy (C) 10 Gy with dose rates of 20, 400 and
2400 cGy/min. Clonogenic survival was accessed as a measure for irradiation efficiency.
Experiments were done in triplicates and repeated at least four times. *p 6 0.05;
**p 6 0.001
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experiment, we changed delivery time as well as dose per pulse at the same time, there-
fore we performed two additional experiments where we changed PRF or DPP separately.
5.3.2 The use of the flattening filter-free beam more efficiently de-
creases tumour cell survival
Recent publications state that delivery time is one of the most prominent factors influ-
encing cancer cell survival during radiation therapy [77,82,83]. Until recently, technical
challenges made it difficult to perform experiments to distinguish whether an effect on
cancer cell survival was caused by delivery time or dose per pulse.
In order to examine if the above observation on cancer cell survival is caused by the
different beam profile of the flattened versus FFF beam, we modified in our next ex-
periment DPP as well as PRF while keeping the mean dose as well as the delivery time
the same (figure 5.3 A). This experiment was performed at a DR of 400 cGy/min since
it is the only dose rate available for both beams. Again, T98G and U87-MG cells were
irradiated with either X10 or X10 FFF with 5 or 10 Gy using a dose rate of 400 cGy/min.
Colony formation assays revealed reduced survival rates after irradiation with the X10FFF
beam compared to the cells irradiated with the X10 beam (figure 5.3 B and C), which
was statistically significant when treating with 10 Gy. The reduction in cell survival
after irradiation with 10 Gy, although still significant, was lower in the U87-MG cells.
This result prompted us to investigate whether this phenomenon is dose dependent,
meaning the higher the single dose, the more pronounced the cancer cell survival di-
verges within the two beams. We irradiated U87-MG cells using either X10 or X10FFF
with 400 cGy/min (figure 5.3 D). Interestingly, the data revealed that when escalating
the single dose while keeping the mean dose and delivery time identical between the two
beams, irradiation with the X10FFF beam showed a statistically significant reduction
of clonogenic survival compared to the treatment with the X10 beam at a dose of 10 Gy
and above and this effect was more distinct the higher the single dose. While we do not
see any difference in cell killing at a dose level of 5 Gy, which is a commonly used dose in
clinical palliative treatment schedules, we see a striking difference in our in vitro model
comparing X10 and X10FFF using high single doses as frequently used in stereotactic
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Figure 5.3: Flattening filter-induced reduction in cell death after irradiation. (A)
Treatment schedule with same mean dose and delivery time, but changes in PRF and
DPP. (B, C) T98G (empty bars) and U87-MG (filled bars) cells were irradiated with
(B) 5 Gy or (C) 10 Gy with a dose rates of 400 cGy/min with either the X10 or
the X10FFF beam and survival measured by colony survival assay. Experiments were
done in triplicates and repeated seven times. (D) Dose-response curve of U87-MG
cells irradiated with either the X10 (full circles) or X10FFF (empty circles) beam.
Clonogenic survival was accessed as a measure for irradiation efficiency. *p 6 0.05;
**p 6 0.001
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treatment regimens such as 10, 15 and 20 Gy.
5.3.3 Increased dose per pulse reduces clonogenic survival
As previously described, removal of the flattening filter leads to a decrease of the mean
energy of the FFF beam [42]. The flattening filter contributes to a partial absorption of
low energy photons irradiation and therefore to a hardening of the beam. Consequently,
removing the flattening filter leads to a reduction in the mean energy. The effective
energy of the X10 FFF is approximately comparable to a flattened 8 MV beam. The
data described may therefore be an effect of the different beam characteristics of FFF
and flattened beam. To test this hypothesis, we irradiated T98G (figure 5.4 B) and
U87-MG (figure 5.4 C) cells with 5 and 10 Gy using the X10 and the X10FFF beams
in a setup where we reduced the dose per pulse of the X10FFF beam to the level of
the X10 beam using additional attenuation material (see Material and methods) and
the dose was delivered with the same number of pulses per minute (figure 5.4 A). As
shown in figure 5.4 B and C, we did not find any statistical significance between these
two treatment schedules. Cells irradiated with the X10FFF beam in the dose-reduction
setup showed the same clonogenic survival as cells irradiated with the X10 beam.
5.3.4 Influence of PRF on cancer cell survival
This raises the question whether treating the cell lines using the same DPP but different
PRF influences colony cell formation. We therefore treated the two cell lines with the
X10 FFF beam either with 400 or 2400 cGy/min (figure 5.4 D). There was only a slight
statistical significance when treating the U87-MG cells with 5 Gy using 400 cGy/min
compared to 2400 cGy/min, but no significance in the T98G cells treated with 5 or 10
Gy nor in the U87-MG cells treated with 10 Gy (figure 5.4 E and F). These data suggest
that changing PRF does not seem to impact cancer cell survival in radiation therapy.
5.3.5 Comparison with the Γ-LQ model
For both cell lines, T98G and U87-MG, the Γ-LQ model in principle is able to fit the
clonogenic survival at 5 and 10 Gy. For the T98G cell line, the following parameters are
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Figure 5.4: Flattening filter-induced reduction in cell death depends on the dose per
pulse, but not on dose rates. (A) Beam characteristics used in experiment B and C. (B,
C) T98G(A) and U87-MG (B) cells were irradiated with 5 and 10 Gy with either the
X10 (empty bars) or the X10FFF beam including reduced dose per pulse (filled bars).
Clonogenic survival was accessed as a measure for irradiation efficiency. (D) Beam
characteristics used in experiment E and F. (E, F) T98G (empty bars) and U87-MG
(filled bars) cells were irradiated with (E) 5 Gy or (F) 10 Gy with dose rates of 400 and
2400 cGy/min using the FFF beam. Clonogenic survival was accessed as a measure for
irradiation efficiency. *p 6 0.05
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used for fitting (figure 5.5): α = 0.03 Gy−1, β = 0.04 Gy−2) and γ = 0.556 min−1 for a
constant dose rate R = 2400 cGy/min and γ = 0.361 min−1 for R = 400 cGy/min. For
a constant dose rate R = 20 cGy/min, γ has to be adapted to a value of 0.0313 min−1.
The use of a pulsed delivery according to the beam characteristics in table 5.1 leads to
the same clonogenic survival. In contrast to the experimental findings in figures 5.3 and
5.4, the computer simulation reveals no difference in the cell survival curve between the
two different pulse patterns at 400 cGy/min. A similar behaviour can be observed for
the U87-MG cell line (with α = 0.018 Gy−1, β = 0.04 Gy−2). At a dose rate of 2400
cGy/min, a good fit is reached with γ = 0.486 min−1 for both, constant dose rate and
pulsed dose application. If the dose rate is reduced to 400 cGy/min by adapting the
PRF to 60 Hz or by the continuous dose rate, γ has to be adapted to 0.208 min−1.
Figure 5.5: Surviving fraction of T98G-glioblastoma cells at different dose rates. For
24Gy/min, the Γ-LQ-model can fit the experimental data with α=0.03Gy−1, β = 0.04
Gy−2 and γ = 0.556 min−1; for 4 Gy/min, γ has to be adapted to 0.361 min−1 and for
R = 0.2 Gy/min, a good fit can only be achieved by adapting the kinetic constant to
γ = 0.0313 min−1.
5.4 Discussion
The results presented here show that clonogenic survival is statistically reduced if the
total dose is delivered with a higher dose per pulse. Indeed, cells irradiated using ei-
ther the X10 or X10FFF beam show a difference in clonogenic survival which can be
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explained by the higher dose per pulse delivered by the X10FFF.
Radiation-induced double-strand breaks (DSB) are the most harmful lesions that arise
after irradiation because of their impact on genome stability and cell survival [91]. The
delivery of higher doses per pulse might reduce cell survival by an increase in DNA dam-
age induction, especially an increase in DSB [92,93]. Recent publications suggest that a
higher dose per pulse might lead to so far unknown changes in proteins and fatty acids,
as well as organelles which have been found to play an important role in the induction of
cell death induced by irradiation [94–96]. Investigating the role of the unfolded protein
response in the endoplasmic reticulum or cytoplasm might therefore give further insights
on the potential mechanism of action of high doses per pulse. Of special interest is how
normal tissue as well as in vivo tumour models are impacted by modulating the dose
per pulse to further elucidate the clinical relevance of the observation described in this
paper. In addition it would be of interest how dose per pulse differs depending on the
molecular background of the normal as well as the tumour tissue and if it plays a role
in low-dose ionizing radiation [97–100].
In contrast to the experimental observations, the Γ-LQ model reveals no difference for
both, cell lines between pulsed and continuous dose application. This is an indication,
that the use of second order kinetics is a simplistic approximation for a limited range of
dose rate. There are possibly different repair mechanisms at different time scales lead-
ing to a dose rate and PRF dependent cell killing. Especially very fast repair processes
or components of the repair system (typically with kinetic constants above 103 min−1)
could be responsible for the sensitivity of the cellular system to the pulse pattern, as
demonstrated in figures 5.3 and 5.4. Pulsed beam characteristics should be included in
bio-mathematical models. Therefore, the use of kinetic models such as the Γ-LQ model
is recommended to include the correct time dependent course of dose delivery.
More data is needed to better understand the effect of modified dose rates on tumour as
well as on normal tissue, and to develop refined bio-mathematical models for clonogenic
cell survival.
Chapter 6
Dosimetric comparison of
flattened and unflattened beams
for stereotactic ablative
radiotherapy of stage I non-small
cell lung cancer1
6.1 Introduction
Stereotactic body radiotherapy (SBRT) has become a standard for treatment of inoper-
able early stage non-small cell lung cancer (NSCLC) [101]. This is based on numerous
phase I/II clinical studies demonstrating high local control rates and good tolerability
for this novel treatment strategy. Less obvious is the question, which of the several
available SBRT techniques is most advantageous. Key parameters to evaluate SBRT
planning and delivery are conformity of dose distribution, organ sparing and treatment
time. The latter is of great importance, since prolonged treatment sessions have been
associated with intrafractional shifts in patient and tumor positioning [102, 103]. Sub-
stantially shortened SBRT delivery with at the same time improved conformity has been
1This chapter has been accepted for publication in Medical physics [31]: J. Hrbacek, S. Lang, S.
Graydon, S. Klo¨ck and O. Riesterer, “Comparison of flattened and unflattened beams for stereotactic
ablative radiotherapy of stage I non-small cell lung cancer.” (The exact citation is not yet known.)
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demonstrated for RapidArc SBRT (Varian Medical Systems, Palo Alto, USA) in com-
parison to conventional static field SBRT [104,105]. RapidArc is a volumetric modulated
arc technique (VMAT) that allows for fast planning and treatment delivery [106].
More recently, linear accelerators with flattening filter free (FFF) beams were introduced
into clinical operation. FFF beams are characterized by high dose rates and their com-
bination with advanced delivery techniques such as VMAT allows further improvement
of treatment delivery efficiency. FFF beams are most frequently utilized for treatments
where higher fraction doses need to be delivered, including hypofractionated SBRT of
stage I-II non-small cell lung cancer (NSCLC), metastases of lung and liver, and other
abdominal tumors [42,107–112].
In parallel to the planning studies, there is also the first data appearing on acute toxi-
cities experienced by patients treated with FFF beams. There is an acceptable degree
of early toxicities, not significantly different from treatment with conventional beams,
reported for treatment in thorax and liver [70] or SBRT of lung malignancies [113]. This
evidence is supported by radiobiological studies [30, 114–116] that report comparable
cell survival between conventional and high dose rate FFF beams for various cell lines.
Though most studies focus primarily on the enhancement in delivery efficiency, changes
in the dosimetric outcome attributed to FFF beams remain an interesting topic. In
comparison to conventional beams of the same nominal energy, FFF beams exhibit
non-uniform profile, lower mean energy, reduced head scatter and leakage, less energy
variation in lateral direction, and differences in penumbra. In addition, there is an inter-
play effect between a beam’s dose rate, fraction dose, and machine parameters such as
speed of MLC leaf motion and gantry rotation, in case FFF beams are combined with
advanced techniques, such as IMRT or VMAT. For these reasons, beam comparison is
not a trivial task and may depend on an interaction of machine/beam characteristic and
various site specific parameters, such as size and location of treatment target, presence
of inhomogeneities, organ motion, etc.
Here we present a planning comparison of VMAT versus FFF VMAT SBRT for treat-
ment of early stage lung cancer. We performed the comparison in rigorous fashion to
assess exclusively the contribution coming from the interchange of treatment beam.
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6.2 Material and Methods
In total 11 patients with stage I (T1-T2 N0 M0) non small cell lung cancer were en-
rolled into the study prospectively as they were registered for treatment in our clinic.
There is relatively wide variation in volume and location of PTV across the group of
patients, however, a rigid stratification of patients is not ensured. Motion encompassing
tumour volumes (internal target volume, ITV) and normal tissues were contoured on
4-dimensional computed tomography images and the ITV was expanded by 5 mm to
create a planning target volume (PTV). The PTV size ranged from 10.1 cm3 to 144.5
cm3 (median of 34 cm3).
For each case, three VMAT plans were prepared utilizing a 6 MV flattened photon beam
(X6FF) and two non-flattened beams of nominal energy 6 MV and 10 MV (X6FFF,
X10FFF) for a TrueBeam STx linear accelerator (Varian Medical Systems).
VMAT is delivered in two coplanar 360° arcs with 90° angular separation of the colli-
mator. An avoidance sector was used to spare the contralateral lung. Using the beams
eye view, the avoidance sector was defined, when the PTV passes entirely behind the
contralateral lung. Treatment plans were generated using Eclipse treatment planning
system (Varian Medical Systems) using the Progressive Resolution Optimizer and Ana-
lytical Anisotropic Algorithm (PRO & AAA, version 8.9, Varian Medical Systems). For
each beam the maximum available dose rate was used, i.e. 600 MU/min, 1400 MU/min,
and 2400 MU/min for X6FF, X6FFF, and X10FFF, respectively. Basic characteristics
of the beams and the accuracy of their modeling using the AAA under physics conditions
have been described in [42]. Optimization constraints were set to produce dose distri-
butions that meet the criteria of the RTOG-0915 protocol [117]. Optimization started
from the common setting, however, the constraints were progressively enhanced for each
plan individually. The radiation schedule used for plan comparison in all patients was
50 Gy in 5 fractions. According to the RTOG protocol at least 95 % of the PTV should
obtain the prescription dose and 99 % receive at least 90 % of the prescription dose (45
Gy). Target inhomogenity was partially controlled by setting a weak constraint on the
maximum dose to the PTV, however, the priority was to generate a steep dose gradient
outside of the PTV. The dose fall-off was controlled by a supporting margin structure,
a 20 mm thick envelope around PTV with a 3 mm separation from PTV. A single con-
straint limiting the maximum dose to the structure was applied. The maximum dose to
the margin structure was gradually reduced during the optimization until the point it
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would affect the PTV coverage.
Further, organ specific dose constraints have been defined: spinal cord <30.0 Gy, oesoph-
agus <32.5 Gy, heart <35 Gy, lung V20Gy <10 %, lung V12.5Gy <15 %, and contralateral
lung V5Gy <25 %.
For each patient, plans utilizing X6FF, X6FFF and X10FFF beams were prepared. The
dose calculation grid of AAA was 2.5 mm. Plans were normalised to the maximum
dose within a PTV. The relative reference isodose (%RX) that ensures sufficient PTV
coverage was determined. The following parameters were used to quantify the resultant
dose distributions:
• number of monitor units (MU)
• mean dose rate (DR)
• minimum, mean, and maximum dose to ITV
• relative reference isodose (%RX)
• dose to healthy tissue ( DHT = body - PTV)
• conformity indexex (CI100%, CI80%, CI60%, CI50%): ratio of the volume enclosed
by the 50Gy, 40Gy, 30Gy, and 25Gy isodose and VPTV , respectively
• ratio of the volume enclosed by 25 Gy isodose and VPTV ( V25Gy/ VPTV )
• maximum dose at any point 2 cm or further away from the PTV ( D2cm)
• gradient measure (GM): mean distance between the 50 Gy and the 25 Gy isodose
• V20Gy and V12.5Gy for both lungs
• V5Gy for the contralateral lung
• Dose2 to spinal cord, oesophagus, brachial plexus, heart, great vessels, trachea,
large bronchus, and rib
Values of the investigated parameters obtained for X6FFF and X10FFF plans were
related to the corresponding X6FF plans. The ratios are denoted as X6FFF/X6FF
2For OARs, maximum dose to an organ (Dmax) and also dose received by 1% of organ’s volume
(D1%) have been determined in order to obtain a more robust estimate of the highest doses within an
OAR.
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and X10FFF/X6FF. The Kolmogorov-Smirnov test was used to check if the parameters
are normally distributed. This hypothesis was rejected for all parameter sets; therefore
the non-parametric two-sided paired Wilcoxon signed-rank test was applied to compare
parameters obtained for FFF beams with the ones of the flattened beam.
All plans were subject to the routine pre-treatment verification process using the Delta4
unit (Scandidos, Uppsala, Sweden). Reference dose distribution for the pre-treatment
verification was calculated with a 1.2 mm grid. Gamma agreement Scores (GS) for a
dose difference of 3% and a distance to agreement of 2 mm were determined. In order
to check the dose distribution calculation in more clinically relevant conditions, i.e. in
the presence of low density tissue, selected plans were also subject to a verification using
absolutely calibrated gafchromic films (EBT2, ISP, Wayne, USA) in a thorax phantom
(CIRS, Norfolk, USA).
6.3 Results
All plans have a qualitatively comparable outcome. There are only minor differences
observed in achieved dose distributions and corresponding dose volume histograms when
comparing the three plans (X6FF, X6FFF, and X10FFF) related to the same patient
(figure 6.1).
In 9 out of 11 patients, all criteria specified by the RTOG protocol were met. In 2
patients, the rib dose was exceeded due to these being part of, or adjacent to, the PTV.
Obtained dose distributions are conformal (CI100% <1.17) and exhibit steep dose fall-off
outside of the PTV (mean GM of 11.74 mm). A summary of dosimetric analysis aver-
aged over the group of plans utilizing the same beam is provided in table 6.2.
RX% ranged between 70 % and 80 %, having the largest spread for X10FFF plans. The
maximum difference in the inhomogeneity among the three plans corresponding to one
patient (X6, X6FFF, and X10FFF) was between 0.5 % and 6.5 %. It was not observed
that the inhomogeneity within a target would be influenced by the beam selection in a
systematic fashion. Similarly, ITV coverage does not change significantly with the beam
selection. The point of maximum dose appears within ITV for all plans, despite the
fact it was not controlled by any constraint. The ratio of monitor units for FFF versus
FF plans in our study ranges from 0.95 to 1.21 and from 0.93 to 1.25 for X6FFF/X6FF
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Figure 6.1: Comparison of dose distribution for X6FFF (left), X6FF (middle),
X10FFF (right) plan in one transverse slice (upper row) and detail of high dose re-
gion (lower row).
and X10FFF/X6FF comparisons, respectively. The ratio systematically increases with
increasing size of the PTV (up to +25 % for 150 cm3 PTV). Yet the DHT does not
follow this trend (figure 6.2).
Comparison of cumulative dose volume histograms for a patient’s body shows that
X6FFF plans exhibit improved conformity and reduce the volume of tissue that re-
ceives more than 50% of the prescription dose. Parameters related to dose gradient
show statistically significant improvement (table 6.1, figure 6.3). CI50%, CI60%, CI80%,
and CI100% are on average reduced by 4.6 % (p <0.001), 4.6 % (p = 0.002), 3.1 % (p
= 0.002), and 1.2 % (p = 0.039), respectively. Gradient measure is on average reduced
by 4.2 % (p <0.001). Due to dose reduction in the surrounding lung tissue, the V20Gy
and V12.5Gy are reduced by 5.5 % (p = 0.002) and 4.5 % (p <0.001). These dosimetric
improvements in the fall-off were not observed for the X10FFF plans. Differences in
sparing of normal tissues were not found to be statistically significant for either of the
two FFF beams.
Delivery of X6FFF and X10FFF plans exhibits reduced treatment time. Whereas mean
beam-on time was 111 s ± 11 s) for X10FFF, 128 s ± 19 s for X6FFF, and X6FF plans
require on average 269 s ± 71 s. While the mean dose rate was 1555 ± 264 MU/min,
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Figure 6.2: Comparison of a) number of MU and b) dose to healthy tissue for
X6FFF/X6FF and X10FFF/X6FF. The X6FF beam represents the reference.
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Figure 6.3: Comparison of the cumulative dose volume histrograms for the body
structure of 11 patients for X6FFF/X6FF (A) and X10FFF/X6FF (B). Comparison of
volume receiving less than 10 Gy is not displayed due to limited calculation accuracy
of TPS in this region. Red lines correspond to ±3 SD.
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Table 6.1: Overview of statistically significant dosimetric parameters for the plan
comparison between the three energies (mean ± 2SD [min - max]
Parameter mean ratio p
CI50% X6FFF/X6FF 0.954 ± 0.050 [0.914 - 0.994] <0.001
lung V12.5Gy X6FFF/X6FF 0.955 ± 0.039 [0.920 - 0.986] <0.001
CI60% X6FFF/X6FF 0.954 ± 0.040 [0.920 - 0.977] 0.002
CI80% X6FFF/X6FF 0.969 ± 0.027 [0.950 - 0.989] 0.002
lung V20Gy X6FFF/X6FF 0.945 ± 0-051 [0.917 - 1.000] 0.002
GM X6FFF/X6FF 0.958 ± 0.036 [0.930 - 0.983] 0.004
MU X6FFF/X6FF 1.061 ± 0.151 [0.946 - 1.214] 0.024
D2cm X6FFF/X6FF 0.980 ± 0.041 [0.947 - 1.008] 0.024
CI100% X6FFF/X6FF 0.988 ± 0.023 [0.971 - 1.010] 0.039
1368 ± 63 MU/min, for X10FFF and X6FFF, plans using the conventional X6FF were
delivered with the constant maximum dose rate of 600 MU/min.
Verification of all plans showed acceptable and comparable results for all plans in ho-
mogeneous as well as heterogeneous phantoms. Mean GS (3 %, 2mm) using the Delta4
phantom were 98.9 % (2SD = 3.2 %), 99.2 % (2SD = 2.3 %), and 99.2 % (2SD = 2.3
%) for X6FFF, X6FF and X10FFF modalities respectively. Verification using a thorax
phantom showed GS >98 % in all cases.
6.4 Discussion
To our knowledge, the first reported study on utilizing FFF beams for NSCLC comes
from Vassiliev et al [42]. This study was carried out with a FFF prototype obtained by
modifying a Clinac 21EX. The dose calculation used was a pencil beam algorithm with
Batho power law inhomogeneity correction. The authors reported that the utilization of
a FFF beam yields a comparable dose distribution and reduces treatment time. However,
due to the rather experimental setup and limited accuracy of the used algorithm, this
early study can be understood as a proof of principle rather than a clinically relevant
comparison. Ong et al [107] performed a study with 10 stage I NSCLC patients. Clinical
plans were delivered with a 6 MV beam from a Novalis TX with HDMLC (Varian
Medical Systems, Palo Alto, USA). Re-planning utilised a 10 MV FFF beam from a
TrueBeam accelerator with Millenium MLC (Varian Medical Systems, Palo Alto, USA),
hence combining different machines as well as MLCs with different leaf thickness. Apart
from increased number of monitor units and decreased treatment time, there was not a
significant difference observed between the obtained dose distributions. The 6 MV FFF
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beam was not utilized arguing by increased skin dose. Navaria et al [108] compared
clinical outcomes for 10 MV FFF VMAT and 6 MV FF 3D-CRT for stage I NSCLC
patients. This study demonstrated reduced dose to the ipsilateral lung and follow up
data (median of 16 months) showed comparable radiological response.
In addition to the studies above, we extend the comparison by the X6FFF beam, use a
single treatment technique, and keep other machine parameters, which are not associated
directly with treatment beam, unchanged. This paper extends our previous work that
focused mainly on the efficiency of treatment delivery [109].
Results of this study suggest that the X6FFF beam has the potential advantage of
generating more conformal dose distributions than the ones achieved with X6FF and
X10FFF beams. Due to the stochastic character of the optimization, there can be large
local differences in dose to healthy tissue adjacent to the PTV. However, dose deposited
outside this volume has a smooth character and is determined by beam penumbra and
scattered dose. Our previous measurements of beam penumbra and dose outside a
field [28], showed that X6FFF has a slightly sharper penumbra than X6FF or X10FFF
at shallow depths and for small fields, presumably due to the shorter range of less
energetic secondary particles. At the same time, X6FFF is more prone to scattering
due to lower mean energy and therefore its penumbra may exceed that of X6FF or
X10FFF, if depth and field size are sufficiently large. From this perspective, we assume
that X6FFF plans benefit from the combination of utilizing the least energetic beam
and the shallow water equivalent depths encountered for NSCLC patient group due to
the presence of lung tissue. In agreement with Ong et al [107], other than reduction of
delivery time, we did not observe any statistically significant change of the evaluated
dosimetric parameters of X10FFF plans in comparison with X6FF plans.
Early studies showed a reduction of monitor units when using FFF beams. Vassiliev
et al [118] reported an average reduction of monitor units by a factor 2.0 for a 6 MV
prostate IMRT on a Clinac 21 EX (Varian Medical Systems) FFF prototype. Similarly,
Stathakis et al [119] reported an example of a 6 MV IMRT on a Clinac 23 EX (Varian
Medical Systems) for lung and prostate, where monitor units for FFF plans were reduced
by a factor 2.6. This effect originated from a different approach to the calibration of
beams. In these studies, the removal of the flattening filter was not followed by a re-
calibration, therefore the dose contribution of 1 MU increased proportionally with the
increase of beam output.
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TrueBeam requires individual calibration of each bundle. Our beams are calibrated to
deliver 1 cGy/MU to the reference point under the reference conditions (SSD 90 cm,
depth 10 cm, field size 10x10 cm2), therefore the inequality in the MU “strength” is
eliminated (at least in respect to the dose delivered to the reference point) and the
number of MU for all plans is comparable. The increase of MU for FFF plans for larger
PTVs is associated with the conical profile of FFF beams. With increasing field size,
dose needs to be deposited at larger distances from the beam’s central axis where FFF
fields deliver less dose per MU than FF fields and this effect needs to be compensated
by increasing the number of MU.
Our previous measurements showed that FFF beams increase dose to skin by up to 10
% depending on energy, depth, and field size [28]. Increased surface dose of FFF beams,
in accordance with our findings, was reported in [120], with author’s stating that the
increase in the surface dose is unlikely to be clinically significant. Our current clinical
results support this statement as we do not observe a higher degree of skin reaction in
patients treated with the X6FFF beam.
It should be noted that treatment planning systems in general are known to perform
with limited accuracy in the low dose region. Howell et al [121] demonstrate approxi-
mately 30 % dose underestimation for one specific plan at the distance of 3 cm from the
edge of a treatment field using one of the preceding versions of AAA. This corresponds
with the analysis of our commissioning data where we observe up to 20 % in local dose
in the tails of measured and TPS modeled profiles (measured up to 5 cm beyond a field’s
edge). The differences vary with energy, field size, and depth of measurement. For these
reasons, regions receiving less than 10 Gy (20 % of the prescription dose) was removed
from our comparison.
An assessment of changes in peripheral doses is not trivial and is typically determined ex-
perimentally or by Monte Carlo simulation. While in the proximity of a treatment field
edge, peripheral dose is mainly determined by scattered photons, at larger distances,
it depends primarily on radiation leakage of an accelerator’s head. Kragl et al [122]
reported a 23% and a 31% reduction in peripheral dose when the flattening filter is
removed for 6 MV and 10 MV lung SBRT plans, respectively. However, a substantial
clinical benefit from reduction of low dose exposure by use of FFF beams in terms of
less radiation induced secondary cancers is unlikely in the case of lung cancer.
Results of the pre-treatment verification are comparable for both flattened and unflat-
tened beams, and in agreement with previously published results [123].
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The reduction of treatment delivery time remains the most obvious benefit of FFF
beams. In this study, the maximum dose rate of 1400 MU/min of the X6FFF beam
appears to be sufficient for the delivery of 10 Gy/fx distributed over two 360-degree
arcs. The optimizer does not make use of the additional dose rate range available for
the X10FFF beam (up to 2400 MU/min). The mean dose rate of X10FFF plans is only
14 % higher than the one of X6FFF plans and the average delivery time gets shorter on
average by 17 seconds. The situation could be potentially different for higher fraction
dose or in case the speed of gantry rotation would increase. Another option could be
utilizing partial arcs, hence delivering the same fraction dose over a shorter arc length.
However, such plans could potentially be more prone to motion interplay effects. It was
demonstrated [124, 125] that increasing of arc length (using a double-arc instead of a
single-arc) improves the robustness of a plan to intrafractional motion.
Generally, high dose rate beams need to be utilized with a caution when applied for
the treatment of moving targets. The ability of FFF beams to deliver treatment more
efficiently in the end means that substantial dose can be delivered to a wrong place in
a short time, if motion management is not carried out properly. It was demonstrated
that even short duration intrafractional shifts can cause significant dosimetric devia-
tions during vertebral SBRT [126]. On the other hand, faster treatment time may be an
important contribution in an attempt to reduce tumor position uncertainty related to
intrafractional motion [109] and may allow for relatively easy implementation of treat-
ment during a few consecutive breath holds [127].
6.5 Conclusion
The use of FFF beams for stereotactic radiation therapy of NSCLC patients yields dose
distributions qualitatively comparable to flattened beams and significantly reduces treat-
ment delivery time. Utilizing the X6FFF beam improves conformity of dose distribution.
On the other hand, X10FFF beam offers a slight improvement in treatment efficiency,
and lower skin and peripheral dose. All effects are relatively small.
Chapter 7
The use of photon beams of a
flattening filter-free linear
accelerator for hypofractionated
volumetric modulated arc therapy
in localized prostate cancer1
7.1 Introduction
The possibility of a low α/β-ratio for prostate cancer provides a radiobiological ad-
vantage for hypofractionated radiotherapy (RT) with excellent local control and low
toxicity [128]. Intensity modulated RT (IMRT) and volumetric-modulated arc therapy
(VMAT) are used to reduce doses to bladder and rectum while maintaining optimized
dose coverage and conformity of the planning target volume (PTV) [129]. Compared
with three-dimensional conformal RT (3D-CRT), these highly conformal treatments re-
quire more monitor units (MU) and increased treatment time. There is also increased
leakage and scatter dose from the linear accelerator (LINAC) multileaf collimator (MLC)
1This chapter has been published as a manuscript [32]: D. R. Zwahlen, S. Lang, J. Hrbacek, C.
Glanzmann, S. Kloeck, Y. Najafi, T. Streller, G. Studer, K. Zaugg, and U. M. Luetolf, “The use of
photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc
therapy in localized prostate cancer,” International Journal of Radiation Oncology* Biology* Physics,
vol. 83, no. 5, pp. 1655-1660, 2012.
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outside the treatment volume resulting in a higher whole-body dose [130]. Increasing
head shielding and removing the flattening filter reduces head leakage and scatter. In
particular, removal of the flattening filter reduces number of photon interactions within
the gantry and increases dose delivery efficiency [20].
TrueBeam STx (Varian Medical Systems, Paolo Alto, CA) is a new platform of LINAC
designed to deliver flattened, as well as flattening filter-free (FFF), beams [28]. Histori-
cally, the flattening filter provided a relatively flat beam profile over the entire treatment
field and dose distributions were calculated in a simplified way. With beam intensity-
modulated techniques, including IMRT and VMAT, the MLC is used to modify the
fluence distribution producing optimal fluence maps for FFF beams similar to those
with a flattening filter [20, 23]. Interest in FFF technology is resulting from the expec-
tation that it will allow faster treatment delivery with dose rates up to 24 Gy/min [26].
Several studies summarized the properties of FFF beams of various LINACs based on
Monte Carlo simulations or dosimetric measurements [23,24,28,57,119,131]. Few studies
however have investigated the feasibility of using FFF beams for IMRT treatment plan-
ning [42,118,119,131]. The studies were performed for prototype LINAC and treatment
planning systems with preclinical release and showed comparable IMRT dosimetric plan
quality for FFF compared with flattened beams.
This is the first treatment planning study investigating hypo-fractionated VMAT with
6 MV and 10 MV FFF photon beams in a clinically released setting for patients with
localized prostate cancer.
7.2 Materials and methods
7.2.1 Patient selection and contouring
This planning study included the computed tomographies of 7 patients with localized
prostate cancer. After ethics approval, men were treated in the CHHiP trial (Conven-
tional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate
Cancer, The Institute of Cancer Research, Sutton, Surrey, UK) at the University Hos-
pital Zurich. Patients were randomized between conventional radiation therapy (74 Gy
in 37 fractions) and the experimental groups of 60 Gy in 20 fractions and 57 Gy in 19
fractions (treating 5 days per week) [132]. All patients were treated with RapidArc plans
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Table 7.1: Volumes for planning target volumes, organs at risk, and dose constraints,
Volume (ccm) Mean (± 1 SD) Range Dose constraints
PTV 1 202.5 (± 29.0) 149.0 - 238.2 V99% ≥ 76% of PD, mean (PTV1-PTV2) ≥ 80% of PD
PTV 2 136.1 (± 31.5) 101.3 - 198.3 V99% ≥ 91% of PD, mean (PTV1-PTV2) ≥ 96% of PD
PTV 3 75.3 (± 16.1) 56.3 - 104.1 V99% ≥ 95% of PD, V99% ¡ 105% of PD
Rectum 129.9 (± 31.3) 134.7 - 334.0 V68% ≤ 60%, V81% ≤ 50%, V95% ≤ 15%, V100% ≤ 3%
Bladder 253.6 (± 68.8) 107.9 - 198.9 V68% ≤ 50%, V81% ≤ 25%, V100% ≤ 5%
Urethral bulb V68% ≤ 50%, V81% ≤ 10%
Femoral heads V68% ≤ 50%
Bowel V68% ≤ 17 ml
Abbreviations: ccm = cubic centimeter; PD = prescribed dose; PTV = planning target volume.
and 6MV flattened beams in 2010.
Contouring of target volumes and organs at risk (OAR) was performed using the CHHiP
protocol, version 8 [132]. Gross tumour volume (GTV) included the prostate only, whilst
the clinical target volume (CTV) 1 included the prostate and base of seminal vesicles
proximal 2 cm) with 5-mm margin or prostate and seminal vesicles with 5-mm margin
for patients with risk of seminal vesicle involvement. CTV 2 encompassed the prostate
only with a 5-mm margin, whilst CTV 3 included the prostate only. For all CTV’s, 5-
mm margins were used to generate PTV’s 1-3, with PTV’s 2 and 3 having a 0-mm, there
was 0-mm margin posteriorly or posterior inferiorly. OARs outlined included bladder,
rectum, bowel, femoral heads, urethral bulb, and skin. All generated PTV and OAR
volumes are summarized in table 7.1.
7.2.2 Photon beams
Treatment planning was performed using four photon beams of TrueBeam STx LINAC.
Beams with nominal energies of 6 MV and 10 MV with flattening filter in the beam
path (X6 and X10) and FFF beams (X6FFF, X10FFF) were investigated. A detailed
description of these beam characteristics is reported elsewhere [31]. The removal of the
flattening filter had several implications on the beam properties including a non-flat
beam profile, an increase in maximal dose rate of up to 14 Gy/min for X6FFF and 24
Gy/min for X10FFF as well as a decrease in mean radial energy (TPR20/10: X6 0.667,
X6FFF 0.631, X10 0.738, X10FFF 0.692) because there was no beam hardening. As a
measure of beam energy, the beam quality index TPR20/10 (ratio of the tissue phantom
ratio at 20 cm and 10 cm) was used.
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7.2.3 Treatment planning
The prescribed dose in all cases was 19 x 3 = 57 Gy. Four VMAT plans (RapidArc)
were calculated for each patient using the Eclipse External Beam Planning System (PRO
8.9, AAA 8.9, Varian Medical Systems). The plans were normalized such that PTV3
received a mean dose of 100% of the prescribed dose. Dose constraints were specified
in the CHHiP trial protocol [132] and are reported in table 7.1. One 360 ° arc (n = 3)
was used to fullfil the constraints with maximum dose rate of 600 MU/min for flattened
beams and 1,200 MU/min for unflattened beams. A second arc (n = 4) was added in
case constraints could not be met. For single arc plans, the collimator angle was 45°,
whereas for the two arcs plans, the collimator angle was 90°. Objectives for OAR were
interactively lowered during optimization for X6 beams without compromising target
coverage. After achieving a satisfactory set of constraints, plans for all four energies
were optimized using these constraints. The final dose calculation was performed with
Eclipse AAA 8.9 algorithm and a calculation grid size of 2.5 mm.
7.2.4 Plan evaluation and statistical methods
Plan evaluation was performed according to the CHHiP trial protocol [132]. MU, mean
body dose, surface dose (cumulative dose in the first 2 mm of the body), mean doses to
rectum and bladder, conformity index (volume enclosed by the prescription isodose/tar-
get volume) of PTV 1, ratio of volume receiving 50% of dose to PTV 1, and treatment
time were recorded.
Plans using X6FFF, X10FFF, and X10 beams were compared with the X6 base plan
and ratios of acquired dosimetric parameters recorded. Statistical analysis was per-
formed with MATLAB, version 7.6, software (MathWorks, Natick, MA). Mean values
and standard deviation of the mean (SD) were collected. Relative dosimetric changes
were compared applying the nonparametric Wilcoxon signed-rank test. A two-sided p
value 0.05 was considered statistically significant. Confidence intervals (CI) included
95% of the measured data. Box-whisker plots were created for selected data, showing
ratios of X6FFF, X10FFF, and X10 beams to X6 beam.
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Table 7.2: MU, dose parameters, and beam-on time (mean ±1 SD)
X6 X6FFF X10 X10FFF
Number of MUs 897 (± 202) 951 (± 141) 718 (± 88) 896 (± 133)
Mean body dose (Gy) 8.52 (± 2.40) 8.83 (± 2.46) 8.06 (± 2.36) 8.27 (± 2.32)
Mean dose to rectum (Gy) 55.6 (± 3.6) 55.7 (± 3.2) 57.0 (± 3.8) 55.6 (± 4.11)
Mean dose to bladder (Gy) 36.2 (± 7.7) 36.7 (± 8.0) 36.0 (± 8.3) 35.5 (± 8.0)
Conformity PTV 1 1.38 (± 0.11) 1.39 (± 0.12) 1.38 (± 0.12) 1.38 (± 0.13)
Inhomogeneity PTV 3 7.1 (± 0.99) 7.9 (± 0.85) 6.9 (± 0.78) 7.6 (± 1.51)
Beam-on time (min)* 1 min, 47 sec 1 min, 34 sec 1 min, 43 sec 1 min, 34 sec
Abbreviations: FFF = flattening filter-free; MU = monitor units; PTV = planning target volume
Includes patients treated with one and two arcs, mean values are calculated for all patients.
7.3 Results
7.3.1 Dose distribution and PTV coverage
For all treatment plans, there were only minor differences in dose distributions using
X6FFF, X10FFF, X10, and X6 beams. No difference was detected between the four
beam qualities with respect to PTV coverage and conformity (figure 7.1). Target inho-
mogeneity was increased by 1% for X6FFF and X10FFF beams compared with flattened
beams (figure 7.2), and below the expected specification of 10% (table 7.2).
Figure 7.1: Box-whisker plots for different dose parameters. Ratio of X6 flattening
filter-free (FFF) (top), X10FFF (middle), and X10 (bottom) with X6. The red line
represents the median value, the blue box the interquartile range, and the whiskers
minimum and maximum. PTV = planning target volume.
7.3.2 MU and mean body dose
The mean body dose decreased significantly with increasing mean energy of the beam (r2
= 0.8275, p <0.01; figure 7.3). Using X6FFF beam delivered 3.6% more dose compared
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Figure 7.2: Planning target volume (PTV) inhomogeneity (defined as Dmax - Dmin
in PTV 3) for the four different energies. Inhomogeneity is increased for flattening
filter-free (FFF) beams.
with the X6 beam (p <0.01, 95% CI = 2.2 to 4.9%), whereas the X10FFF beam delivered
3.0% less dose (p <0.01, 95% CI = -2.3% to 4.7%) and the X10 beam 5.8% less dose (p
<0.01, 95% CI = -3.8% to -7.8%). The volume receiving 50% of the prescribed dose to
PTV 1 decreased significantly with increasing mean energy (figure 7.1).
MU significantly increased for X6FFF by 7.7% (p <0.02, 95% CI = 0.8% to 16.5%), and
for X10FFF by 1.2% (p = 0.7, 95% CI = 8.2% to 9.8%); however, this increase was not
significant. A significant decrease of 18.8% (p <0.02, 95% CI = 4.7% to 30.9%) in MU
for X10 was detected because of the higher mean energy (table 7.2).
Figure 7.3: Mean body-dose dependence on the beam quality. Body dose was nor-
malized to mean body dose of X6 beam.
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7.3.3 Dose to skin and organs at risk
Compared with X6 beams, the mean skin dose significantly increased by 8.2% (p <0.01,
CI = 5.9e11.3%) for X6FFF beams and decreased significantly by 9.1% (p <0.01, CI
= 7.8% to 11.7%) and 12.9% (p <0.01, CI = 9.9% to 14.1%) for X10FFF and X10
beams. There was no difference in mean dose to the rectum and dose parameters V68%,
V81%, V95%, and V100% were not statistically different for X6, X6FFF, and X10FFF
beams (figure 7.1). A significant increase in mean dose of 2.6% (p <0.01, 95%CI = 0.6 -
4.2%) to the rectum was measured for X10 compared with X6 beam energy. The mean
dose to the bladder was increased significantly by 1.3% for X6FFF (p <0.02, 95%CI =
0.1% to 2.2%) and decreased significantly by 2.3% (p <0.02, 95%CI = 0.2% to 3.7%)
for X10FFF; no significant changes were detected for X10 (table 7.2). For the urethral
bulb, there was no difference for V68% and V81% with respect to the four beams, and
V68% for bowel and femoral heads were within the required constraints for all patients
and beam energies.
7.3.4 Treatment time
For plans using a single arc, treatment time was significantly reduced to 1 min when
using X6FFF and 10XFFF beams. The mean treatment time for single arc X6 and
X10 plans were 1 min, 30 s, and 1 min, 25 s (table 7.2). The higher maximum dose
rates for FFF beams allowed the gantry to run at maximum speed during the full arc.
For flattened beams the gantry had to slow down in order to deliver the necessary MU.
There was no difference in treatment time if two arcs were used.
7.4 Discussion
The results of this planning study demonstrated that with hypo-fractionated VMAT,
dose distribution, conformity, and homogeneity within the PTVs were similar using
either flattened or unflattened 6 and 10 MV photon beams. We showed that the mean
body dose was a function of beam energy and decreased with increasing mean energy.
Absence of the flattening filter resulted in a 3.6% higher mean body dose for X6FFF
compared with X6 beams. X10FFF decreased the mean body dose by 3% compared with
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the X6 beam; however, it increased the mean body dose by 2.8% compared with X10.
For the rectum, the mean organ dose increased for the 10 MV unflattened photon beam
compared with the 6 MV beams. Interestingly, usage of X10FFF decreased mean bladder
dose compared with the other three beam qualities. Finally, using FFF technology,
treatment time for a single arc was significantly reduced because of increased dose rate
and faster delivery time.
Ensuring high-quality 3D-CRT, homogeneous photon fluence across the treatment field
is of high priority to achieve optimal PTV coverage and a flattening filter was needed
to ensure homogeneous target coverage. However, with the introduction of MLC’s,
changing leaf positions across the field modulates photon fluence to achieve optimal
fluence maps [23, 119]. Thus, a uniform beam is no longer necessary as comparable
treatment planning results for either flattened or unflattened beams have been reported
[26], in particular for smaller treatment fields used in extracranial stereotactic RT for
lung cancer [42]. Vassiliev et al. reported in their planning study, that using 6 and
18 MV IMRT with and without flattening filter resulted in similar treatment plans
regarding PTV coverage for prostate cancer. Depending on the beam energy, X6FFF
produced superior IMRT plans than X6. X18FFF resulted in inferior plans compared
with X18 because of larger differences between optimal and deliverable fluence maps
when compared with 6 MV [118]. However, plans and treatment delivery parameters
were not fully optimized for FFF beams and the authors state that improvement of
PTV coverage for either plan might have been possible with different user-specific cost
functions for either the PTV or organs at risk. Similarly, Stathakis et al. observed
negligible differences in PTV coverage between flattened and FFF 6 and 18 MV IMRT
prostate plans. As expected, our data confirmed the authors finding that superficial
dose was decreasing with increasing mean energy [119]. Compared with our study,
both groups [118,119] implemented IMRT techniques with FFF beams on a nonclinical
prototype LINAC. Using VMAT technique, we found similar results: PTV coverage
was unchanged using flattened or unflattened beam. However, we could detect a small
difference of 1% in PTV inhomogeneity for FFF beams (figure 7.2). At this stage, it is
unknown if the measured target inhomogeneity has any clinical relevance for treatment
outcome of future patients with localized prostate cancer. Applying tighter objectives
in the planning optimization process may reduce target inhomogeneities. However, we
designed our study keeping all treatment planning objectives constant for all four beam
energies.
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For flattened beam-intensity modulation treatments, including IMRT and VMAT, the
number of MU needed is an indicator for the mean body dose [133]. We found that a
higher number of MU for FFF beams compared with flattened beams did not necessarily
lead to an increased mean body dose. Because of the non-flat profile of the FFF beam,
the integral dose of open fields in a water phantom is smaller than for a flattened beam
in relation to 100 MU (figure 7.4). This finding was more pronounced with increasing
field size. Therefore, compared with X6 an increase in MU for FFF beams was expected.
Indeed, the planning study showed that the number of MU increased for X6FFF and
X10FFF by 7.7% and 1.2%. In contrary, Vassiliev et al. [118] as well as Stathakis et
al. [119] found a significant decrease in the number of MU for their FFF treatment plans.
The reason was that our FFF beams were calibrated in order that 100 MU corresponded
to 1 Gy at the depth of maximum dose, as this was common for flattened beams [51].
However, for all prototype LINACs with FFF capabilities used by other groups, only
the flattened beams were calibrated. This resulted in a higher dose per 100 MU for the
unflattened beams. Therefore they report a decrease in number of MU that we could
not confirm in our study. Our data demonstrated that the mean body dose slightly
decreased with the mean energy of the beam, despite the increase in number of MU that
did not affect the mean body dose.
Figure 7.4: Integral dose of open fields in a water phantom relative to X6 beam
corresponding to 100 MU for different field sizes.
Use of beam-modulating techniques exposes the whole body to a larger amount of scat-
tered low-dose radiation as significant parts of treatment fields are being blocked by
Appendix 7: FFF VMAT in localized prostate cancer 94
the MLC increasing MU and scatter dose [130]. Prostate cancer patients treated with
IMRT might be exposed to a twofold increased risk of developing secondary malignancies
compared with 3D-CRT [130]. It is expected that FFF beams compared with flattened
beams deposit less dose outside the target volume because of the missing scatter from
the flattening filter and the reduced head scatter [58,118,122,131].
Kragl et al. demonstrated that using FFF beams for IMRT prostate treatments re-
sulted in a reduction of treatment head leakage by 52% and 65% for 6 and 10 MV,
respectively [122]. Similarly, Cashmore et al. found in their study that IMRT using
FFF beams removed unwanted and unnecessary scatter dose from the treatment head
and lowered peripheral dose by up to 70% [131].
When applying hypofractionated treatment regimens for localized prostate cancer, treat-
ment delivery time is important. With flattened beams and a limited output of MU/min
higher doses per fraction leads to longer beam-on time and organ motion becomes rele-
vant [134]. We found a time advantage for both FFF beams compared with X6 beam if
one arc was used for planning. If the gantry was running at maximum speed, the time
needed for one arc was 1 min. Flattened beams can deliver in 1 min 600 MU, X6FFF
1400 MU, and X10FFF 2400 MU. Therefore, whenever more than 600 MU per arc are
needed, FFF beams reduce treatment time compared with flattened beams. The number
of MU needed for the 7 patients ranged between 564 MU and 803 MU (for X10) and 803
MU to 1283 MU (for X6). For FFF beams, the number of MU was slightly increased.
Therefore there is a time advantage for both FFF beams compared to X6 beam if one
arc is used for planning. Fu et al. found a time advantage for FFF IMRT treatments
of 46% depending on the dose per fraction. The time advantage increased when using
higher dose per fraction, but was insignificant for standard fractionation of 2 Gy [26].
For sliding window IMRT the potential benefit of high dose rate is limited by the speed
of the MLC. For treatments with RapidArc gantry speed is the limiting factor.
Finally, this study has several limitations. Our findings were based on a planning, rather
than a clinical study. It is known that treatment planning systems do not correctly model
the low-dose region [135]. Therefore the expected advantage of FFF beams to reduce
the dose outside the target volume is not shown in our planning study. At this time,
our results may be interpreted as having theoretical value rather than showing a clinical
benefit for patients. However, this study revealed that non-inferior VMAT plans could
be generated to deliver fast and high-quality hypofractionated RT. We acknowledge the
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relevance and importance of image-guidance for modern prostate cancer RT when com-
bining hypofractionated VMAT, high dose rate, and fast delivery time because of organ
motion; however, this was beyond the scope of this article. Finally, as we carefully an-
alyzed the differences and their impact on treatment planning and delivery, we believe
our study contributes to a better understanding of the differences between flattened and
unflattened beams in future clinical use.
7.5 Conclusion
For treatment plans with RapidArc, FFF beams resulted in dose distributions similar to
flattened beams. We showed that X10FFF photon beams showed advantages in sparing
rectum and bladder as well as keeping whole-body dose low. This could positively affect
the treatment’s toxicity profile using hypofractionated RT and may help to reduce the
risk of second malignancies. Importantly, the use of FFF beams reduced treatment
time, when gantry speed was a limiting factor for faster delivery of VMAT treatment.
With increasing dose per fraction, higher dose rate might be used to reduce treatment
time ever further. The described advantages of hypofractionated VMAT combined with
unflattened photon beams should be tested in a clinical trial demonstrating the benefits
for patients with localized prostate cancer.
Chapter 8
General conclusions
Flattening filter free (FFF) beams represent a new treatment modality of C-arm linear
accelerators. In the scope of this thesis, several specific areas have been investigated in
order to asses the contribution of FFF beams to clinical radiation therapy.
Measurements of the dosimetric characteristics of FFF beams are summarized and dis-
cussed in Chapter 3. This work may be considered as the reference overview of FFF
and conventional beam properties of TrueBeam linear accelerator (Varian Medical Sys-
tems). The corresponding manuscript [28] has been in the meantime frequently cited1
by various research groups. The same chapter also deals with the accuracy of beam
modeling. Despite the fact that the Analytical Anisotropic Algorithm (Varian Medical
Systems) has been simplified for FFF beams, it was shown that FFF beams are modelled
with an accuracy comparable to the one known for conventional beams. These findings
confirm the previous premise that the absence of flattening filter could make modeling
of FFF beams more straightforward (less changes in the energy spectrum, reduction of
extra-focal photons, etc.) Quantitative assessment of dose profile and depth dose curve
modeling accuracy was possible owing to the modified 1D γ-concept (Chapter 2). This
method was originally developed to identify small discrepancies between modeled and
measured dose profiles of conventional beams, but it was successfully applied to FFF
beams as well thanks to its universal character.
Commissioning measurements required a revision of dosimetric characteristics of ion-
ization chambers with respect to the high dose rates of FFF beams (Chapter 4). The
1There are 36 citations reported by Scopus, abstract and citation database of peer-reviewed literature,
in February 2014.
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collection efficiency of all examined air-vented chambers was found to be sufficiently
high to allow reliable assessment of relative dosimetry and correction factors for abso-
lute dosimetry were less than 1 % in all cases. However, ion-collection efficiency was
found to be insufficient for an iso-octane-filled ionization chamber when utilized for FFF
beams and this chamber cannot be recommended for relative dosimetry of these beams.
Radiobiological effects associated with FFF beams have been studied on two human
glioblastoma cell lines (Chapter 5). It was found that clonogenic survival was signifi-
cantly reduced, if the total dose is delivered with a higher dose per pulse while keeping
the mean dose rate constant. It was further demonstrated that X10FFF and X10 with
the same dose per pulse do not exhibit differences in survival, hence the difference in the
killing efficiency cannot be contributed to changes in energy spectrum. Pulse repetition
frequency did not influence the survival.
Treatment planning studies assessing the contribution of FFF beams to stereotactic
ablative radiotherapy of stage I non-small cell lung cancer (Chapter 6) and to localized
prostate radiation therapy (Chapter 7) have also been carried out. Both studies showed
that conventional and FFF beams yield quantitatively comparable dose distributions
and only minor dosimetric differences were found. However, significant improvement in
treatment delivery efficiency was observed for FFF plans in both studies.
In the case of the lung study, plans utilizing X6FFF beams showed a minor advantage in
the steepness of dose gradient on the boundary between PTV and surrounding healthy
tissue, which resulted in slightly improved sparing of ipsilateral lung tissue. In the case of
the prostate study, plans utilizing X10FFF beams showed advantages in sparing rectum
and bladder as well as keeping whole-body dose low. It was also demonstrated that both
sets of beams exhibit comparable accuracy of treatment delivery.
Radiation therapy with flattening filter free (FFF) beams is gradually expanding. An in-
creasing number of studies shows that FFF based radiation therapy is moving in routine
clinical operation. FFF beams are most frequently utilized for treatments where high
fraction doses need to be delivered, especially hypofractionated stereotactic radiother-
apy (SRT) of stage I-II non-small cell lung cancer (NSCLC), lung and liver metastases,
and other abdominal tumors [108–112]. In addition, FFF beams have been utilized
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for the treatment of breast and chest wall [136, 137], esophageal cancer [138], local-
ized prostate cancer [32], spinal radio surgery [139], brain lesions [140], nasopharyngeal
carcinoma [141], etc.
Neglecting some site specific differences, it is possible to state, based on the available
evidence, that the utilization of FFF beams provides dose distributions that are compa-
rable to the ones achieved with conventional (flattened) beams, but with the advantage
of significantly reduced time of treatment delivery. Shorter delivery times are surely
increasing patient’s comfort during treatment and can favorably reduce uncertainties
in the patient positioning, or allow easier handling of tumor motion during treatment
delivery (intrafractional motion). Indeed, it has been demonstrated on an 8-field FFF
IMRT technique for lung and liver that faster delivery time makes it feasible to treat
high doses per fraction delivering each field during a single breath-hold [127].
However, high dose rate beams need to be utilised with a caution when applied for
the treatment of moving targets. The ability of FFF beams to deliver treatment more
efficiently in the end means that substantial dose can be delivered to a wrong place in
a short time, if motion management is not carried out properly. It was demonstrated
that even short duration intrafractional shifts can cause significant dosimetric deviations
during vertebral SBRT [126].
For treatments in the abdomen, the lower dose rates of conventional beams allow sta-
tistical “smearing” of motion interplay effects over many breathing cycles. One possible
solution for high dose rate FFF beams is to distribute the treatment over multiple parts
(in the inter- as well as intra-fractional sense). It has been shown that, although a sin-
gle VMAT arc delivered at 2400 MU/min is susceptible to motion interplay, using two
arcs and at least two fractions reduces the effect to a level that appears unlikely to be
clinically significant [124,125].
This examples illustrate that the application of FFF beams for a specific treatment site
needs to be considered in the context of the rest of the radiotherapeutic chain and their
mutual interplay.
In parallel to the planning studies, there is also the first data appearing on acute toxic-
ities experienced by patients treated with FFF beams. There is an acceptable degree of
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early toxicities, not significantly different from treatment with conventional beams, re-
ported for treatment in thorax and liver [70], SBRT of lung malignancies [113], intensity
modulated radio surgery of brain metastases [142], and prostate [143]. This evidence is
supported by radiobiological studies [114–116,144] that report comparable cell survival
between conventional and high dose rate FFF beams for various cell lines.
These studies did not confirm our previous findings that an increase in dose per pulse
(instantaneous dose rate) decreases cell survival [30]. One of the possible explanations
could be a difference in used cell lines, especially when considering that the dependence
of survival on dose per pulse varied even between the two cell lines used within our
experiment. With the exception of T98G used in [114], all above mentioned studies used
different cell lines for their experiments. Karan et al [116] add differences in cell cycle
synchronisation as another possible explanation. However, from the overview of these
studies, it seems that applied fraction dose could play an important role. Our study
showed statistical difference only for single doses of 10 Gy or higher. The maximum
fraction dose was 8 Gy in [115], 10 Gy in [116] and [144], and 12 Gy in [114]. Depending
on selected cell line, survival at higher doses is relatively low (units of % or less) and
could be biased by poor statistics and/or a presence of sterile cells in the experiment,
impurities, etc. For the lower doses, where the surviving fraction allowed robust statistic,
survival also did not differ in our study.
Despite the fact our study confirmed statistically significant difference in survival, this
difference was unlikely to be clinically important, especially when taking into account
standard dose per fraction and the fact that radiation therapy is delivered in a fraction-
ated regime and not as a single fraction dose.
Despite the recent move towards more clinical studies, various aspects of the physi-
cal characteristics of FFF beams are continuing to be investigated. Georg et al [145]
provided a comprehensive summary of the status of FFF related research in 2011. In
addition, centers that first began to use FFF beams with TrueBeam linear accelerator
presented a joint study on the results of patient specific QA [123], demonstrating that
treatment delivery with FFF beams is as accurate as those for conventional beams.
A reduction of out-of-field (peripheral) doses associated with the reduction of head
scatter and leakage has been evaluated [122] in clinically relevant conditions (lung SBRT,
prostate and head&neck IMRT). At about 20 cm from the field edge, the dose was
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reduced by more than 20 %. The relative difference increases with the nominal beam
energy.
The dose calculation accuracy of FFF beams has been found to be comparable to the
ones known for conventional beams [146]. A study focussing on the accuracy of modeling
of FFF beams in a heterogeneous lung/tissue phantom [147] found an overestimation
of penumbral width for very small fields incident on tissue equivalent material located
within lung [147]. It was demonstrated that FFF beams exhibit rather small off-axis
variations in energy, potentially allowing to ignore these changes in a treatment plan-
ning system [57]. Slightly increased surface dose of FFF beams was reported [120], in
accordance with our findings, with the author’s stating that the increase in the surface
dose is unlikely to be clinically significant.
Various detectors have also been compared to alanine detector for the dosimetry of small
fields of FFF beams [148]. The determined output factors were found to agree within
the measurement uncertainty or only a small correction was required. Another study on
ion-recombination of specific ionization chambers in FFF beams was published [149] and
further improvements in Monte Carlo simulations, such as adapting the virtual source
model to mimic a FFF beam production [150], have been achieved.
The concept of a direction-selective flattening filter - a small conical filter in the proximity
of a target - has also been proposed [151]. The authors claim it represents a solution
midway between classical and FFF beams, taking advantage of increased dose rate and
reduced leakage while preserving a flat beam profile for field sizes up to 15 cm diameter.
In summary, the current clinical evidence appears to fulfill the expectations based on
the previous theoretical assumptions and experiments done with FFF prototype linacs.
The main advantages of FFF beams are improved efficiency of treatment delivery and
the reduction of unwanted scatter dose. Available data suggests that there is not a
necessity to apply any radio-biological corrections. With ongoing clinical experience,
further optimization of the treatment modality is expected. While FFF beams have
expanded the dose rate range, other components utilized in modulated radiation therapy,
such as speed of a multi-leaf collimator and rotational speed of a gantry, have remained
the same. It is the author’s opinion that further enhancements of treatment planning
optimization algorithms or hardware changes that will exploit higher dose rates, may
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contribute to further improve the outcome of FFF radiation therapy. However, these
improvements are likely to be marginal.
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